Myriad Genetics (MYGN) 10-K 25 Feb 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Feb. 18, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	0-26642
Entity Registrant Name	MYRIAD GENETICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0494517
Entity Address, Address Line One	320 Wakara Way
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84108
City Area Code	801
Local Phone Number	584-3600
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	MYGN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 2,376,886,737
Entity Common Stock, Shares Outstanding		80,022,885
Entity Central Index Key	0000899923
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Documents Incorporated by Reference	The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K:  Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement, to be filed no later than 120 days following December 31, 2021, for the Annual Meeting of Stockholders to be held on June 2, 2022.

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	Salt Lake City, UT
Auditor Firm ID	42

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 258.4	$ 117
Marketable investment securities	81.4	33.7
Trade accounts receivable	91.3	89.5
Inventory	15.3	27.1
Prepaid taxes	18.4	108.4
Prepaid expenses and other current assets	20	13.7
Total current assets	484.8	389.4
Operating lease right-of-use assets	81.8	59.7
Long-term marketable investment securities	59	21
Property, plant and equipment, net	43.5	40.7
Intangibles, net	404.1	576.5
Goodwill	239.2	329.2
Other assets	8.3	2.3
Total assets	1,320.7	1,418.8
Current liabilities:
Accounts payable	29.6	20.5
Accrued liabilities	156.5	79.1
Current maturities of operating lease liabilities	13	13.6
Deferred revenue	5.2	32.7
Total current liabilities	204.3	145.9
Unrecognized tax benefits	27.9	30.5
Long-term deferred taxes	35.8	71.3
Long-term debt	0	224.8
Noncurrent operating lease liabilities	79.3	50.6
Other long-term liabilities	5.6	14.7
Total liabilities	352.9	537.8
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value, 80.0 and 75.4 shares outstanding at December 31, 2021 and 2020, respectively	0.8	0.8
Additional paid-in capital	1,226.3	1,109.5
Accumulated other comprehensive loss	(5.1)	(2.3)
Accumulated deficit	(254.2)	(227)
Total Myriad Genetics, Inc. stockholders' equity	967.8	881
Non-controlling interest	0	0
Total stockholders' equity	967.8	881
Total liabilities and stockholders’ equity	$ 1,320.7	$ 1,418.8

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Statement of Financial Position [Abstract]
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, shares outstanding	80	75.4	74.7	73.5	70.6

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Total revenue	$ 299.8	$ 690.6	$ 638.6	$ 851.1
Costs and expenses:
Research and development expense	35.8	81.9	77.2	85.9
Selling, general, and administrative expense	260.4	537.8	507.3	556.6
Legal charges pending settlement	0	62	0	0
Goodwill and long-lived asset impairment charges	0	1.8	99.7	0
Total costs and expenses	387.6	881.1	870.3	843.5
Operating income (loss)	(87.8)	(190.5)	(231.7)	7.6
Other income (expense):
Interest income	0.7	0.7	3	3.2
Interest expense	(5.8)	(6.6)	(10.8)	(12)
Other	(1.2)	139.3	16.2	1.2
Total other income (expense)	(6.3)	133.4	8.4	(7.6)
Income (loss) before income tax	(94.1)	(57.1)	(223.3)	0
Income tax benefit	(41)	(29.9)	(23.7)	(4.4)
Net income (loss)	(53.1)	(27.2)	(199.6)	4.4
Net loss attributable to non-controlling interest	0	0	(0.1)	(0.2)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (53.1)	$ (27.2)	$ (199.5)	$ 4.6
Earnings (loss) per share:
Basic (in dollars per share)	$ (0.71)	$ (0.35)	$ (2.69)	$ 0.06
Diluted (in dollars per share)	$ (0.71)	$ (0.35)	$ (2.69)	$ 0.06
Weighted average shares outstanding:
Basic (weighted average shares)	75	78	74.3	73.5
Diluted (weighted average shares)	75	78	74.3	76
Molecular diagnostic revenues
Total revenue	$ 279.6	$ 666.4	$ 586.9	$ 789.4
Costs and expenses:
Costs and expenses	82.6	185.7	157.5	168.2
Pharmaceutical and clinical services
Total revenue	20.2	24.2	51.7	61.7
Costs and expenses:
Costs and expenses	$ 8.8	$ 11.9	$ 28.6	$ 32.8

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Statement of Comprehensive Income [Abstract]
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (53.1)	$ (27.2)	$ (199.5)	$ 4.6
Unrealized gain (loss) on available-for-sale securities, net of tax	(0.5)	(1)	0.7	1.2
Change in pension liability	0	0	0	0.6
Change in foreign currency translation adjustment, net of tax	3.4	(1.8)	(0.6)	(3.1)
Comprehensive income (loss)	$ (50.2)	$ (30)	$ (199.4)	$ 3.3

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive income (loss)	Retained earnings (accumulated deficit)
Beginning balance at Jun. 30, 2018	$ 966.1	$ 0.7	$ 915.4	$ (4.1)	$ 54.1
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax	136		136
Stock-based payment expense	33.5		33.5
Repurchase and retirement of common stock	(50)		(16.9)		(33.1)
Net income (loss)	4.6				4.6
Other comprehensive income (loss), net of tax	(1.3)			(1.3)
Ending balance at Jun. 30, 2019	1,088.9	0.7	1,068	(5.4)	25.6
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax	3.4		3.4
Stock-based payment expense	25.2		25.2
Net income (loss)	(199.5)				(199.5)
Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary	0.1			0.1
Other comprehensive income (loss), net of tax	0.1			0.1
Ending balance at Jun. 30, 2020	918.2	0.7	1,096.6	(5.2)	(173.9)
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax	(1.9)	0.1	(2)
Stock-based payment expense	14.9		14.9
Net income (loss)	(53.1)				(53.1)
Other comprehensive income (loss), net of tax	2.9			2.9
Ending balance at Dec. 31, 2020	881	0.8	1,109.5	(2.3)	(227)
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax	80.3		80.3
Stock-based payment expense	36.5		36.5
Net income (loss)	(27.2)				(27.2)
Other comprehensive income (loss), net of tax	(2.8)			(2.8)
Ending balance at Dec. 31, 2021	$ 967.8	$ 0.8	$ 1,226.3	$ (5.1)	$ (254.2)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (53.1)	$ (28.9)	$ (27.2)	$ (223.6)	$ (199.5)	$ 4.6
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	35.8		62.8		72	73
Non-cash interest expense	0.4		1.5		0.5	0.4
Non-cash lease expense	6.4		12.8		0	0
Stock-based compensation expense	14.9		36.3		25.2	33.5
Deferred income taxes	44.2		(32.1)		(55.8)	18.6
Unrecognized tax benefits	7.1		(2.6)		1.7	(5.5)
Non-cash impact of foreign currency transactions	(1)		0		0	0
Loss on inventory	0		6.5		0	0
Impairment of goodwill and long-lived assets	0	1.3	1.8	98.4	99.7	0
Gain on sale of businesses and assets	0		(162)		(1)	0
Payment of contingent consideration	0		0		0	(1.5)
Changes in assets and liabilities:
Prepaid expenses and other current assets	3.1		(6.6)		2.8	(3.9)
Trade accounts receivable	(21.4)		(8.8)		64	(18.2)
Inventory	2.2		1.6		1.6	8
Prepaid taxes	(108.4)		89.9		25.1	(25.1)
Other assets	(2.3)		(4)		0	0
Accounts payable	(1.2)		9.2		(10.7)	1.1
Accrued liabilities	(0.2)		65.7		4.4	(0.8)
Deferred revenue	(0.2)		(26.6)		30.7	(0.5)
Net cash provided by (used in) operating activities	(73.7)		18.2		60.7	83.7
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	(7.9)		(18)		(10.2)	(8.6)
Acquisitions, net of cash acquired	0		0		0	(278.5)
Proceeds from sale of business and assets	0		379.1		21.3	0
Purchases of marketable investment securities	0		(147.8)		(60.8)	(78.5)
Proceeds from maturities and sales of marketable investment securities	35.9		61.1		69	79.2
Net cash provided by (used in) investing activities	28		274.4		19.3	(286.4)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from common stock issued under stock-based compensation plans	1.8		91.8		13.3	23.2
Payment of tax withheld for common stock issued under stock-based compensation plans	(3.8)		(11.5)		(9.8)	(14.5)
Payment of contingent consideration recognized at acquisition	(0.1)		(3.3)		(3.9)	0
Proceeds from revolving credit facility	0		0		0	340
Fees associated with refinancing of revolving credit facility	0		(1.2)		(1)	(1.4)
Repayment of revolving credit facility	0		(226.4)		(8.6)	(115)
Repurchase and retirement of common stock	0		0		0	(50)
Net cash provided by (used in) financing activities	(2.1)		(150.6)		(10)	182.3
Effect of foreign exchange rates on cash and cash equivalents	1.1		(0.6)		0.5	2.7
Net increase (decrease) in cash and cash equivalents	(46.7)		141.4		70.5	(17.7)
Cash and cash equivalents at beginning of the period	163.7	$ 93.2	117		93.2	110.9
Cash and cash equivalents at end of the period	$ 117		$ 258.4	$ 117	$ 163.7	$ 93.2

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Financial Statement Presentation Myriad Genetics, Inc. and subsidiaries (collectively, the "Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical specialties. The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters are located in Salt Lake City, Utah. The accompanying consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“GAAP”) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. Use of Estimates The preparation of the consolidated financial statements in accordance with GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates. The full impact of the COVID-19 outbreak continues to evolve and its future impacts remain uncertain and unpredictable. The Omicron variant, which has become the most common form of the virus circulating throughout the world and appears to be more transmissible than other variants to date, is causing significant uncertainty. The impact of the Omicron variant and other variants that may emerge cannot be predicted at this time and could depend on numerous factors, including, but not limited to, vaccination rates among the population, the effectiveness of COVID-19 vaccinations against emerging variants, and any new measures that may be introduced by governments or other parties in response to an increase in COVID-19 cases. Management is actively monitoring the impact of the global situation on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for future periods. Reclassifications Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, cash flows from operations, or net loss for the period. Concentration of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s account receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 17%, 16%, 15% and 14% of total revenue for the year ended December 31, 2021, the six-month transition period ended December 31, 2020 and the years ended June 30, 2020 and 2019, respectively. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. No customer accounted for more than 10% of accounts receivable at December 31, 2021 or December 31, 2020. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions. Marketable Investment Securities The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company’s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash. A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company’s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the year ended December 31, 2021, the transition period ended December 31, 2020 or during the years ended June 30, 2020 and 2019. Inventory Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis. In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company evaluates its inventories for excess quantities and obsolescence. Inventories that are considered excess or obsolete are expensed. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management’s assessment of current and expected orders from the Company’s customers. Trade Accounts Receivable Trade accounts receivable represents amounts billed to customers for revenue recognized related to molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, pharmaceutical and clinical services. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral. Property, Plant and Equipment Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of five one Intangible Assets and Other Long-Lived Assets Intangible and other long-lived assets are comprised of acquired licenses and technology and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The classification of the Company’s acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December 31, 2021 and 2020, the Company had unamortized software costs of $6.7 million and $2.3 million, respectively. For the year ended December 31, 2021, amortization expense for capitalized software costs was $0.2 million. There was no capitalized software amortization expense for the remaining periods presented. The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. Goodwill Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill is first assessed using a qualitative approach. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed. The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results. Revenue Recognition Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the "Clinic") in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. See Note 16 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of clinical and pharmaceutical services indicates transfer of control for revenue recognition purposes. The following table represents the Company’s revenue by type for the year ended December 31, 2021, the transition period ended December 31, 2020, and the years ended June 30, 2020 and 2019: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (In millions) 2021 2020 2020 2019 Molecular diagnostic revenues: Hereditary Cancer $ 316.3 $ 159.3 $ 347.4 $ 479.7 Tumor Profiling 120.9 33.9 48.3 43.0 Prenatal 106.8 37.6 76.7 104.9 Pharmacogenomics 93.7 29.8 74.1 112.6 Autoimmune 28.2 18.0 39.1 48.3 Other 0.5 1.0 1.3 0.9 Total molecular diagnostic revenue 666.4 279.6 586.9 789.4 Pharmaceutical and clinical service revenue 24.2 20.2 51.7 61.7 Total revenue $ 690.6 $ 299.8 $ 638.6 $ 851.1 In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue: Year Ended Six-month Transition Period Ended December 31, 2021 2020 (in millions) U.S. RoW Total U.S. RoW Total Molecular diagnostic revenues: Hereditary Cancer $ 271.0 $ 45.3 $ 316.3 $ 140.9 $ 18.4 $ 159.3 Tumor Profiling 80.4 40.5 120.9 28.2 5.7 33.9 Prenatal 106.2 0.6 106.8 37.4 0.2 37.6 Pharmacogenomics 93.7 — 93.7 29.8 — 29.8 Autoimmune 28.2 — 28.2 18.0 — 18.0 Other — 0.5 0.5 1.0 — 1.0 Total molecular diagnostic revenue 579.5 86.9 666.4 255.3 24.3 279.6 Pharmaceutical and clinical services revenue 24.2 — 24.2 20.1 0.1 20.2 Total revenue $ 603.7 $ 86.9 $ 690.6 $ 275.4 $ 24.4 $ 299.8 Year Ended June 30, 2020 2019 (in millions) U.S. RoW Total U.S. RoW Total Molecular diagnostic revenues: Hereditary Cancer $ 329.8 $ 17.6 $ 347.4 $ 466.7 $ 13.0 $ 479.7 Tumor Profiling 39.2 9.1 48.3 34.6 8.4 43.0 Prenatal 76.4 0.3 76.7 104.9 — 104.9 Pharmacogenomics 74.1 — 74.1 112.6 — 112.6 Autoimmune 39.1 — 39.1 48.3 — 48.3 Other 1.2 0.1 1.3 0.5 0.4 0.9 Total molecular diagnostic revenue 559.8 27.1 586.9 767.6 21.8 789.4 Pharmaceutical and clinical services revenue 36.4 15.3 51.7 37.8 23.9 61.7 Total revenue $ 596.2 $ 42.4 $ 638.6 $ 805.4 $ 45.7 $ 851.1 Under ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally customers make payments prior to the Company's performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During the year ended June 30, 2020, the Company received approximat ely $29.7 million in a dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Deferred revenue - beginning balance $ 32.7 $ 32.8 $ 2.2 $ 2.6 Revenue recognized (40.5) (6.1) (7.2) (7.9) Prepayments 14.0 6.0 37.8 7.5 Divestitures (1.0) — — — Deferred revenue - ending balance $ 5.2 $ 32.7 $ 32.8 $ 2.2 In accordance with Topic 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that are constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of request for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Consolidated Statements of Operations and Comprehensive Income (Loss). Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December 31, 2021, the Company recognized $15.9 million in revenue which resulted in a $0.15 impact to earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December 31, 2021, revenue of $6.8 million was recognized due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period. During the year ended June 30, 2020, the Company recognized a $9.9 million decrease in revenue, which resulted in a $(0.10) impact to earnings (loss) per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the year ended June 30, 2020 resulted in an impact to earnings (loss) per share for the year ended June 30, 2020 of $(0.05). During the transition period ended December 31, 2020, and year ended June 30, 2019, the impact to revenue and earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. In accordance with Topic 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, etc. The Company has elected to apply the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company has also elected to apply the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payments terms have a payback period of less than one year. Stock-based Payment Expense We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with Accounting Standards Codification (“ASC”) 718, Compensation – Stock Compensation. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee’s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company’s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Simulation model. For PSUs, t he Company estimates the likelihood of achievement of the performance conditions at the end of each period. Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of our stock price. Other Income (Expense) The Company recognizes the gain or loss on its divestitures as Other income (expense). During the years ended December 31, 2021 and June 30, 2020, the Company recognized a net gain on divestitures of $162.0 million and $1.0 million, respectively. See Note 16 for additional information regarding these divestitures. In addition, during the year ended June 30, 2020, the Company received approximately $14.6 million, respectively, from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that are attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations. Income Taxes The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company’s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows. Earnings Per Share Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Denominator: Weighted-average shares outstanding used to compute 78.0 75.0 74.3 73.5 Effect of dilutive stock options — — — 2.5 Weighted-average shares outstanding and dilutive 78.0 75.0 74.3 76.0 Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Anti-dilutive options and RSUs excluded from EPS computation 4.5 6.6 5.5 0.8 Foreign Currency The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive income (loss) as a separate component of Stockholders’ equity. The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions): Ending balance December 31, 2020 $ (3.1) Period translation adjustments (1.8) Ending balance December 31, 2021 $ (4.9) Recent Accounting Pronouncements Recently Adopted Standards In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for public companies with fiscal years beginning after December 15, 2020, with early adoption permitted. The guidance was adopted with no material impact to the Company's consolidated financial statements.

Marketable Investment Securitie

Marketable Investment Securities	12 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Marketable Investment Securities	MARKETABLE INVESTMENT SECURITIES The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December 31, 2021 and December 31, 2020 were as follows: (in millions) Amortized Gross Gross Estimated December 31, 2021: Cash and cash equivalents: Cash $ 195.2 $ — $ — $ 195.2 Cash equivalents 63.2 — — 63.2 Total cash and cash equivalents 258.4 — — 258.4 Available-for-sale: Corporate bonds and notes 105.7 0.1 (0.2) 105.6 Municipal bonds 16.1 — — 16.1 Federal agency issues 6.8 — — 6.8 US government securities 11.9 — — 11.9 Total $ 398.9 $ 0.1 $ (0.2) $ 398.8 (in millions) Amortized Gross Gross Estimated December 31, 2020: Cash and cash equivalents: Cash $ 47.9 $ — $ — $ 47.9 Cash equivalents 69.1 — — 69.1 Total cash and cash equivalents 117.0 — — 117.0 Available-for-sale: Corporate bonds and notes 28.8 0.5 — 29.3 Municipal bonds 9.4 0.2 — 9.6 Federal agency issues 4.0 — — 4.0 US government securities 11.7 0.1 — 11.8 Total $ 170.9 $ 0.8 $ — $ 171.7 Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December 31, 2021: (in millions) Amortized Estimated Cash 195.2 195.2 Cash equivalents 63.2 63.2 Available-for-sale: Due within one year 80.3 80.4 Due after one year through five years 60.2 60.0 Due after five years — — Total $ 398.9 $ 398.8 There were no debt securities classified as available-for-sale in a gross unrealized loss position as of December 31, 2021 or December 31, 2020.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The fair value of the Company’s financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2— observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities. Level 3—unobservable inputs. All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the contingent consideration period of approximately 13.5 years, utilizing various potential pay-out scenarios. Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business. The contingent consideration liabilities are classified as a component of Accrued liabilities and Other long-term liabilities in the Company’s Consolidated Balance Sheets. Changes to the contingent consideration liabilities are reflected in Selling, general, and administrative expense in our Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements. The following tables set forth the fair value of the Company’s financial assets and liabilities that are re-measured on a regular basis: (in millions) Level 1 Level 2 Level 3 Total December 31, 2021 Money market funds (a) $ 63.2 $ — $ — $ 63.2 Corporate bonds and notes — 105.6 — 105.6 Municipal bonds — 16.1 — 16.1 Federal agency issues — 6.8 — 6.8 US government securities — 11.9 — 11.9 Contingent consideration — — (8.6) (8.6) Total $ 63.2 $ 140.4 $ (8.6) $ 195.0 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. (in millions) Level 1 Level 2 Level 3 Total December 31, 2020 Money market funds (a) $ 69.1 $ — $ — $ 69.1 Corporate bonds and notes — 29.3 — 29.3 Municipal bonds — 9.6 — 9.6 Federal agency issues — 4.0 — 4.0 US government securities — 11.8 — 11.8 Contingent consideration — — (10.9) (10.9) Total $ 69.1 $ 54.7 $ (10.9) $ 112.9 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. The following table reconciles the change in the fair value of the contingent consideration during the periods presented: (in millions) Year Ended December 31, 2021 Transition Period Ended December 31, 2020 Year Ended June 30, 2020 Year Ended June 30, 2019 Carrying amount at beginning of period $ 10.9 $ 6.8 $ 13.8 $ 14.5 Payment of contingent consideration (3.3) (0.1) (3.9) — Change in fair value recognized in the statement of operations 1.8 3.5 (2.8) (1.1) Translation adjustments recognized in other comprehensive income (loss) (0.8) 0.7 (0.3) 0.4 Carrying amount at end of period $ 8.6 $ 10.9 $ 6.8 $ 13.8

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	PROPERTY, PLANT AND EQUIPMENT, NET December 31, (in millions) 2021 2020 Leasehold improvements 38.0 35.7 Equipment 112.4 117.9 Property, plant and equipment, gross 150.4 153.6 Less accumulated depreciation (106.9) (112.9) Property, plant and equipment, net $ 43.5 $ 40.7 During the year ended December 31, 2021, the Company completed the sales of Myriad RBM, Inc. and the Myriad Autoimmune business, which resulted in the disposition of $3.1 million of property, plant and equipment. See Note 16 for additional information regarding these divestitures. Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Depreciation expense $ 12.1 $ 5.0 $ 11.0 $ 13.7

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	GOODWILL AND INTANGIBLE ASSETS Goodwill The changes in the carrying amount of goodwill for the year ended December 31, 2021 is as follows: (in millions) Year Ended December 31, 2021 Beginning balance $ 329.2 Divestitures (88.5) Translation adjustments (1.5) Carrying amount at end of period $ 239.2 The Company assessed goodwill for impairment as part of its annual goodwill testing in accordance with the appropriate guidance (see Note 1) and determined none of its reporting units were impaired as of the annual testing date. The Company did not record an impairment of goodwill for the year ended December 31, 2021, the transition period ended December 31, 2020 or for the fiscal year ended June 30, 2019. During the year ended June 30, 2020, as a result of the effect of COVID-19 on expected future cash flows and a corresponding decline in market capitalization and enterprise value, the Company performed an interim quantitative impairment review of goodwill for the Myriad Mental Health, Myriad Autoimmune and Myriad International reporting units as of March 31, 2020. Based on this analysis, the Company recognized a goodwill impairment charge of $80.7 million related to the goodwill from the Myriad Autoimmune reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., and as a result the goodwill attributable to the Myriad RBM reporting unit is no longer held by the Company. In addition, on September 13, 2021, select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit were sold. As a result of this divestiture, the goodwill attributable to the Myriad Autoimmune reporting unit is no longer held by the Company. During the year ended June 30, 2020, the Company also recognized a $1.3 million impairment charge for goodwill allocated to the Clinic asset group that is included in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. Intangible Assets Intangible assets have primarily consisted of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as a non-amortizable intangible asset of in-process research and development. Due to the completion of the sales of Myriad RBM, Inc. and the Myriad Autoimmune business, the Company's intangible assets as of December 31, 2021 consist of only purchased licenses and technologies. In connection with these sales, the Company sold $199.1 million in purchased licenses and technologies, $4.8 million in-process research and development intangible assets, $4.7 million in customer relationships, and $3.0 million in trademarks, resulting in an aggregate decrease of intangible assets of $120.0 million, net of $91.6 million in accumulated amortization. See Note 16 for additional information on these divestitures. The Company’s purchased licenses and technologies have estimated remaining useful lives between 1 and 14 years. Prior to the sale of Myriad RBM, Inc., the estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets. The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate during prior years as the related research and development was not yet complete nor had it been abandoned. During the year ended June 30, 2020, the Company decided to abandon the development of one of its in-process research and development intangible assets, and as a result the Company recognized a charge of $17.7 million, which is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. The Company concluded there was no impairment of long-lived assets for the year ended December 31, 2021, the transition period ended December 31, 2020, or for the year ended June 30, 2019. The following tables summarize the amounts reported as intangible assets (in millions): At December 31, 2021: Gross Accumulated Amortization Net Purchased licenses and technologies $ 616.6 $ (212.5) $ 404.1 Total intangible assets $ 616.6 $ (212.5) $ 404.1 At December 31, 2020: Gross Accumulated Amortization Net Purchased licenses and technologies $ 818.2 $ (248.2) $ 570.0 Customer relationships 4.7 (4.5) 0.2 Trademarks 3.0 (1.5) 1.5 Total amortizable intangible assets 825.9 (254.2) 571.7 In-process research and development 4.8 — 4.8 Total unamortized intangible assets 4.8 — 4.8 Total intangible assets $ 830.7 $ (254.2) $ 576.5 As of December 31, 2021 the weighted average remaining amortization period for purchased licenses and technologies is approximately 10 years. The Company recorded amortization during the respective periods for these intangible assets as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Amortization of intangible assets $ 50.7 $ 30.8 $ 61.0 $ 59.3 Future amortization expense of intangible assets as of December 31, 2021 is estimated to be as follows (in millions): Years Ended December 31, Amortization Expense 2022 $ 40.8 2023 40.8 2024 40.8 2025 40.8 2026 40.8 Thereafter 200.1 Total $ 404.1

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued Liabilities	ACCRUED LIABILITIES December 31, (in millions) 2021 2020 Employee compensation and benefits $ 52.8 $ 48.9 Legal charges pending settlement 62.0 — Accrued taxes payable 4.0 4.3 Refunds payable and reserves 9.8 9.3 Short-term contingent consideration 3.2 3.4 Accrued royalties 5.4 3.8 Other accrued liabilities 19.3 9.4 Total accrued liabilities $ 156.5 $ 79.1

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Long-Term Debt	LONG-TERM DEBT On December 23, 2016, the Company entered into a senior secured revolving credit facility (the “Facility”) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility, which effected an “amend and extend” transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million. On May 1, 2020, the Company entered into Amendment No. 2 to the Amended Facility, which waived the Company’s compliance with certain covenants and modified the interest rate and other terms during the modification period from March 31, 2020 through June 30, 2021 (“Modification Period”). On February 22, 2021, the Company entered into Amendment No. 3 (the "Amended Facility"), which, among other things, decreased the maximum aggregate principal commitment from $350.0 million to $300.0 million, with a further reduction in the maximum aggregate principal commitment from $300.0 million to $250.0 million by September 30, 2021 (if not previously reduced to such amount in connection with certain specified asset sales), waived the Company's compliance with certain financial covenants through the quarter ended March 31, 2022, extended the Modification Period for an additional year through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt. The Company's maximum aggregate principal commitment on its Amended Facility is $250.0 million as of December 31, 2021. The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Amended Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balances and the undrawn fee was increased to 50 basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR 150-250 basis points on drawn balances and an undrawn fee ranging from 25 to 45 basis points, in each case, based on the Company’s leverage ratio. The LIBOR floor was also increased to 1.0% during the Modification Period. Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company’s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company’s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. Amendment No. 2 modified the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021. Amendment No. 2 also revised certain negative covenants of the Amended Facility during the Modification Period. Amendment No. 3 waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ended March 31, 2022 and also lowered the minimum liquidity covenant, which was added by Amendment No. 2, to $150.0 million, and made it applicable through such quarter. Amendment No. 3 restricted the Company from borrowing under the Amended Facility if unrestricted cash and cash equivalents exceed $150.0 million, unless such borrowings are in connection with permitted acquisitions. The Company was in compliance with all applicable financial covenants at December 31, 2021.

Other Long-Term Liabilities

Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	OTHER LONG-TERM LIABILITIES December 31, (in millions) 2021 2020 Contingent consideration $ 5.4 $ 7.4 Other 0.2 7.3 Total other long-term liabilities $ 5.6 $ 14.7

Preferred and Common Stockholde

Preferred and Common Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Preferred and Common Stockholders' Equity	PREFERRED AND COMMON STOCKHOLDERS' EQUITY The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at December 31, 2021 and December 31, 2020. The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 80.0 million and 75.4 million shares issued and outstanding at December 31, 2021 and 2020, respectively. Common shares issued and outstanding Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Beginning common stock issued and outstanding 75.4 74.7 73.5 70.6 Common stock issued upon exercise of options and employee stock plans 4.6 0.7 1.2 4.5 Repurchase and retirement of common stock — — — (1.6) Ending common stock issued and outstanding 80.0 75.4 74.7 73.5 Stock Repurchase Program In June 2016, the Company’s Board of Directors authorized a share repurchase program of $200.0 million of the Company’s outstanding common stock. The Company may repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company’s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of December 31, 2021, the Company has $110.7 million remaining on its current share repurchase authorization. The Company uses the par value method of accounting for its stock repurchases. As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to Retained earnings (accumulated deficit). During the year ended June 30, 2019, the Company used $50.0 million to repurchase shares of the Company’s common stock as part of an accelerated share repurchase. The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to Retained earnings (accumulated deficit) for the repurchases for periods ended December 31, 2021, December 31, 2020, June 30, 2020, and June 30, 2019 were as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Shares purchased and retired — — — 1.6 Common stock and additional paid-in-capital reductions $ — $ — $ — $ 16.9 Charges to retained earnings $ — $ — $ — $ 33.1

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	STOCK-BASED COMPENSATIONOn November 30, 2017, the Company’s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock and stock unit awards to employees, consultants and directors. Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant under the 2017 Plan. The 2017 Plan allows for issuance of up to 4.6 million shares of common stock, with 3.6 million shares available for grant as of December 31, 2021. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they will also be available for issuance pursuant to the 2017 Plan. The number of shares, terms, and vesting periods are determined by the Company’s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over four years either on the anniversary of the date on which the RSUs were granted or during the month in which the anniversary occurs. The number of RSUs awarded to certain employees may be increased or reduced based on certain additional performance metrics. Options and RSUs granted to our non-employee directors vest in full upon the earlier of the completion of one year of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options generally vest ratably over service periods of four years. Options granted generally expire ten years from the date of grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire seven years from the grant date. The number of RSUs awarded to certain executive officers and other senior positions that ultimately vest may be increased or reduced based on certain additional performance and market conditions. The performance and market conditions associated with awards granted during the year ended December 31, 2021 include vesting that is based 50% on achieving certain levels of earnings per share targets, and 50% based on achieving certain performance targets compared to the performance of the Nasdaq Health Care Index. The Company estimates the likelihood of achievement of performance conditions at the end of each period. During the transition period ended December 31, 2020, the Company granted stock-based awards to the Company's President and Chief Executive Officer as an inducement material to his commencement of employment and entry into an employment agreement with the Company. The inducement awards are included in the tables presented below. Stock Options A summary of option activity under the Company's equity plans, including the Company's inducement awards, is as follows for the year ended December 31, 2021: (number of shares in millions) Number Weighted Weighted Options outstanding at beginning of period 5.2 $ 23.24 Options granted — — Less: Options exercised (3.7) 24.26 Options canceled or expired (0.1) 25.18 Options outstanding at end of period 1.4 20.36 3.08 Options exercisable at end of period 1.0 23.07 2.09 Options vested and expected to vest 1.4 20.36 3.08 There were no options granted during the years ended December 31, 2021, June 30, 2020, and June 30, 2019. During the transition period ended December 31, 2020, 0.7 million options were granted to the Company's President and Chief Executive Officer, with a weighted average grant fair value of $13.38. The following table summarizes information about stock options outstanding at December 31, 2021 (number of shares in millions): Options outstanding Range of Number outstanding at December 31, Weighted Weighted $13.38 0.7 5.62 $ 13.38 $23.98 0.1 0.18 23.98 $27.07 - 36.55 0.6 0.74 27.25 1.4 3.08 $ 20.38 Restricted Stock Units A summary of the RSU activity under the Company's equity plans, including the Company's inducement awards and RSU awards with performance metrics, is as follows for the year ended December 31, 2021: 2021 (number of shares in millions) Number Weighted RSUs unvested and outstanding at beginning of period 3.2 $ 20.56 RSUs granted 1.8 29.83 Less: RSUs vested (1.1) 21.32 RSUs canceled (0.8) 24.48 RSUs unvested and outstanding at end of period 3.1 $ 24.96 The weighted average grant-date fair value of restricted stock units granted during the year ended December 31, 2021, the transition period ended December 31, 2020, and the years ended June 30, 2020, and June 30, 2019 was $29.83, $13.69, $27.96 and $46.62, respectively. The fair value of restricted stock units that vested during the year ended December 31, 2021, the transition period ended December 31, 2020, and the years ended June 30, 2020, and June 30, 2019 was $22.6 million, $29.1 million, $32.4 million and $27.6 million, respectively. Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Cost of molecular diagnostic testing $ 1.5 $ 0.6 $ 1.2 $ 0.8 Cost of pharmaceutical and clinical services 0.1 0.1 0.3 0.2 Research and development expense 4.2 2.4 5.0 5.4 Selling, general, and administrative expense 30.5 11.8 18.7 27.1 Total stock-based compensation expense $ 36.3 $ 14.9 $ 25.2 $ 33.5 As of December 31, 2021, there was $61.7 million of total unrecognized stock-based compensation expense that will be recognized over a weighted-average period of 2.3 years. We expect all unvested awards to vest, and we recognize forfeitures as they occur. The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows: (in millions) As of Aggregate intrinsic value of options outstanding $ 10.2 Aggregate intrinsic value of options fully vested 4.6 Aggregate intrinsic value of RSUs outstanding 86.3 The total intrinsic value of options exercised was as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Total intrinsic value of options exercised $ 29.2 $ 0.5 $ 8.8 $ 0.4 Employee Stock Purchase Plan The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the “2012 Purchase Plan”), under which 2.0 million shares of common stock have been authorized. On September 23, 2021, the Board of Directors of the Company approved an amended and restated 2012 Employee Stock Purchase Plan, which authorizes an additional 2.0 million shares of common stock and extends the term of the 2012 Purchase Plan to November 30, 2032, subject in each case to obtaining stockholder approval. The amended and restated 2012 Employee Stock Purchase Plan also amended certain provisions of the 2012 Purchase Plan effective upon approval by the Board of Directors, including expanding the definition of "offering period" to provide that the Board of Directors may determine the period in accordance with the terms of the plan, and capping the number of shares that may be purchased by any participant during an offering period at 5,000 shares. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. At December 31, 2021, a total of approximately 2.0 million shares of common stock had been purchased under the 2012 Purchase Plan. Shares purchased under and compensation expense associated with the 2012 Purchase Plan for the years reported are as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Shares purchased under the plans 0.2 0.1 0.3 0.2 Plan compensation expense $ 1.5 $ 0.6 $ 1.7 $ 1.0 The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black‑Scholes option-pricing model using the following weighted-average assumptions: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, 2021 2020 2020 2019 Risk-free interest rate 0.1% 0.2% 1.8% 2.1% Expected dividend yield —% —% —% —% Expected life (in years) 0.5 0.5 0.5 0.5 Expected volatility 60% 94% 99% 55%

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES Income tax benefit consists of the following: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Current: Federal $ (1.9) $ (75.8) $ 26.6 $ (24.2) State 3.6 (0.6) 4.9 (0.1) Foreign 0.1 0.2 0.5 0.2 Total current 1.8 (76.2) 32.0 (24.1) Deferred: Federal (33.7) 39.1 (51.5) 17.8 State 5.1 (3.4) (4.1) 1.7 Foreign 0.1 (0.5) (3.6) 0.4 Change in valuation allowance (3.2) — 3.5 (0.2) Total deferred (31.7) 35.2 (55.7) 19.7 Total income tax benefit $ (29.9) $ (41.0) $ (23.7) $ (4.4) Income (loss) before income taxes consists of the following: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 United States $ (53.8) $ (101.8) $ (240.9) $ (0.6) Foreign (3.3) 7.7 17.6 0.6 Total $ (57.1) $ (94.1) $ (223.3) $ — The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Federal income tax expense at the statutory rate $ (12.0) 21.0 % $ (19.8) 21.0 % $ (46.9) 21.0 % $ — 21.0 % State income taxes, net of federal benefit (1.8) 3.2 % (1.2) 1.3 % 4.0 (1.8) % 2.0 6,422.1 % Research and development credits 2.5 (4.4) % (1.3) 1.4 % (2.8) 1.3 % (3.7) (11,880.9) % Uncertain tax positions (3.0) 5.3 % 0.6 (0.7) % 1.5 (0.7) % (4.2) (13,486.4) % Incentive stock option and employee stock purchase plan expense 0.7 (1.2) % 2.5 (2.7) % (0.2) 0.1 % (3.1) (9,954.3) % Foreign rate differential 0.5 (0.9) % (2.1) 2.2 % 0.7 (0.3) % 0.8 2,568.8 % Change in valuation allowance (3.2) 5.6 % (0.3) 0.3 % 3.5 (1.7) % (0.2) (642.2) % CARES Act 2.7 (4.7) % (20.7) 22.0 % — — % — — % Non-deductible meals and entertainment 0.1 (0.2) % 0.5 (0.5) % 1.8 (0.8) % 1.3 4,174.4 % Non-deductible officer compensation 3.3 (5.8) % 0.1 (0.1) % 1.6 (0.7) % 0.6 1,926.6 % Asset impairment — — % — — % 12.6 (5.6) % — — % Non-deductible legal settlement 2.5 (4.5) % — — % — — % 1.9 6,101.0 % Acquisitions, Dispositions, and Contingent Consideration (23.0) 40.3 % 0.7 (0.7) % (0.3) 0.1 % 0.8 2,568.8 % Method changes or tax elections — — % — — % — — % (0.9) (2,890.0) % Other, net 0.8 (1.4) % — — % 0.8 (0.3) % 0.3 963.4 % Total income tax benefit $ (29.9) 52.3 % $ (41.0) 43.5 % $ (23.7) 10.6 % $ (4.4) -14,107.7 % The significant components of the Company’s deferred tax assets and liabilities were comprised of the following: December 31, (in millions) 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 67.2 $ 72.2 Deferred revenue 1.2 7.2 Stock compensation expense 4.5 11.5 Research and development credits 17.3 24.9 Lease right-of-use asset 22.4 15.2 Accrued expenses and liabilities 14.2 7.6 Other, net 4.5 6.4 Total gross deferred tax assets 131.3 145.0 Less valuation allowance (38.5) (42.0) Total deferred tax assets 92.8 103.0 Deferred tax liabilities: Intangible assets 104.9 144.0 Lease liability 20.2 14.6 Property, plant and equipment 3.5 15.7 Total deferred tax liabilities 128.6 174.3 Net deferred tax liability $ (35.8) $ (71.3) The CARES Act in 2020 made various tax law changes, including among other things (i) increased the limitation under IRC Section 163(j) for 2019 and 2020 to permit additional expensing of interest, (ii) enacted technical corrections so that qualified improvement property can be immediately expensed under IRC Section 168(k) and net operating losses arising in fiscal tax years beginning before January 1, 2018 and ending after December 31, 2017 can be carried back two years and carried forward twenty years without a taxable income limitation as opposed to carried forward indefinitely, and (iii) made modifications to the federal net operating loss rules including permitting federal net operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding taxable years. As a result of the provision provided under the CARES Act, the Company was able to carry-back federal net operating losses to previous periods, resulting in a $20.7 million tax benefit in the year ended December 31, 2020 and $2.7 million tax expense in the year ended December 31, 2021. The Company recognized the sale of Myriad RBM, Inc., Myriad myPath, LLC, and select assets of Crescendo Biosciences, LLC (formerly known as Crescendo Biosciences, Inc. ("CBI") in the year ended December 31, 2021, which resulted in differences between book and tax treatments. This resulted in the recognition of a $187.0 million capital loss for the tax basis in the stock of Crescendo, which the Company utilized in the current year due to the $282.3 million overall capital gain from the three divestitures. Other consequences due to the dispositions were the removal of deferred tax assets and corresponding valuation allowances. The overall net tax benefit of the divestitures during the year ended December 31, 2021 was $23.4 million. As a result of the economic impact of COVID-19, the Company has incurred a cumulative three-year loss. Pursuant to ASC Topic 740, the negative evidence of a cumulative loss may be difficult to overcome. However, the Company will have significant future taxable income resulting from the reversal of taxable temporary differences. Primarily due to the availability of such expected future taxable income, the Company concluded that it is more likely than not that the benefits of the majority of its deferred income tax assets will be realized. However, for certain deferred tax assets a valuation allowance has been established, primarily due to limitations imposed by I.R.C. Section 382 and certain jurisdictional limitations. For the year ended December 31, 2021, the Company's valuation allowance decreased by $3.5 million, primarily due to the expiration of Utah research credits upon which a valuation allowance had been established. The Company will continue to evaluate the impact that the COVID-19 pandemic may have on its results of operations and its ability to realize its deferred tax assets. At December 31, 2021, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions): Carryforwards Amount Subject to Expires Through Federal net operating loss $ 31.2 Yes 2036 2037 Federal capital loss 13.5 No 2026 2026 Utah net operating loss 2.4 No 2022 Indefinite California net operating loss 3.9 Yes 2027 2042 Other state net operating loss 7.4 Yes 2027 2041 Foreign net operating losses (various jurisdictions) 8.8 No Various Various Federal research credit 6.4 Yes 2027 2042 Utah research credit 6.9 No 2022 2036 California research credit 4.0 No Indefinite Indefinite Consistent with the indefinite reversal criteria of ASC 740, the Company intends to continue to invest undistributed earnings of its foreign subsidiaries indefinitely. However, due to the cumulative losses that have been incurred to date in such foreign operations, the changes of the Tax Cuts and Jobs Act and the aforementioned election to treat its foreign subsidiaries as disregarded entities, no deferred taxes related to the Company’s foreign operations have been recorded. For those foreign entities for which an election has been made to be treated as disregarded for U.S. tax purposes, the appropriate U.S. jurisdiction deferred tax assets and liabilities have been recorded. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement criteria as set forth in ASC 740. As of December 31, 2021, the Company had net unrecognized tax benefits of $32.1 million. The Company’s gross unrecognized tax benefits as of the year ended December 31, 2021, the transition period ended December 31, 2020 and the years ended June 30, 2020 and 2019, and the changes in those balances are as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Unrecognized tax benefits at the beginning of period $ 37.6 $ 23.5 $ 21.7 $ 24.9 Gross increases - current year tax positions 1.4 13.9 1.6 2.2 Gross increases - prior year tax positions 1.1 1.0 0.7 0.5 Gross increases - acquisitions — — — 2.3 Gross decreases - prior year tax positions (2.8) (0.1) — (0.1) Gross decreases - settlements (5.1) — — (2.7) Gross decreases - statute lapse (0.1) (0.7) (0.5) (5.4) Unrecognized tax benefits at end of year $ 32.1 $ 37.6 $ 23.5 $ 21.7 Interest and penalties in year-end balance $ 3.3 $ 2.2 $ 1.4 $ 0.8 Interest and penalties related to uncertain tax positions are included as a component of income tax expense and all other interest and penalties are included as a component of other income (expense). The Company files U.S. federal, foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company is currently under audit by the state of California for years ended June 30, 2017-2018; the State of New Jersey for the years ended June 30, 2013-2017; and Switzerland for the years ended June 30, 2015-2016. Annual tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities, including the matters described below. Estimates for resolution of legal and other contingencies are accrued when losses are probable and reasonable estimable in accordance with ASC 450, Contingencies . Qui Tam Lawsuit In June 2016, our wholly-owned subsidiary, CBI, received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act. On January 22, 2020, after a multi-year investigation into CBI’s and the Company’s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company’s motion to dismiss. We have accrued $48.0 million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in Accrued liabilities in the Company's Consolidated Balance Sheet. If no settlement is reached, we intend to continue to vigorously defend against this case, but we cannot predict with any degree of certainty the ultimate resolution of this matter or determine whether, or to what extent, any loss with respect to this matter may exceed the amount that we have accrued. Securities Class Action On September 27, 2019, a class action complaint was filed in the United States District Court for the District of Utah, against the Company, our former President and Chief Executive Officer, Mark C. Capone, and our Chief Financial Officer, R. Bryan Riggsbee (“Defendants”). On February 21, 2020, the plaintiff filed an amended class action complaint, which added our former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned In re Myriad Genetics, Inc. Securities Litigation (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding our business, operations, and acquisitions. The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees. On March 16, 2021, the United States District Court for the District of Utah denied the Company's motion to dismiss. On December 1, 2021, the United States District Court for the District of Utah granted plaintiff's motion for class certification. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any. Stockholder Derivative Actions On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against our former President and Chief Executive Officer, Mark C. Capone, our Chief Financial Officer, R. Bryan Riggsbee, our former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of our current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding our business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any. On September 17, 2021, a second stockholder derivative complaint was filed in the United States District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the United States District Court for the District of Delaware pending the resolution of the securities class action lawsuit. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any. On January 18, 2022, a third stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock and Marcey stockholder derivative actions. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any. Other Legal Proceedings On July 27, 2020, a lawsuit was filed against the Company in the Superior Court of Suffolk County, Massachusetts, by Heide Abelli and Victor Pricolo. The plaintiffs claimed negligence, breach of contract and associated torts in connection with an alleged error in testing performed by the Company in 2004. The plaintiffs sought damages allegedly sustained by them by reason of the allegations set forth in their complaint, together with interest and costs. As of December 31, 2021, we accrued $14.0 million for a potential settlement of this lawsuit, which is included in Accrued liabilities in the Company's Consolidated Balance Sheet as of December 31, 2021. On January 24, 2022, the Company entered into an agreement with the plaintiffs to settle the lawsuit. Pursuant to the terms of the settlement agreement, the Company agreed to pay $14.0 million to the plaintiffs. The settlement agreement also provides for a full release by the plaintiffs of all claims against the Company and contains no admission of liability, wrongdoing or responsibility on the part of the Company. On February 3, 2022, a purported class action lawsuit was filed against the Company in the United States District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. We intend to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any. As of December 31, 2021, the management of the Company believes any reasonably possible liability that may result from the resolution of any other matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows. However, it is possible that the ultimate resolution of other matters, if unfavorable, may be material to the results of operations or financial condition for a particular period. From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	LEASESThe Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from one On July 1, 2019, the Company adopted ASU 2016-02 under the modified retrospective approach by initially applying ASU 2016-02 at the adoption date, rather than at the beginning of the earliest comparative period presented. Results for the year ended December 31, 2021, the six-month transition period ended December 31, 2020 and the year ended June 30, 2020 are presented under ASU 2016-02. Prior period amounts were not adjusted and continue to be reported under previous lease accounting guidance. As part of the adoption, the Company elected the package of practical expedients to avoid reassessing prior conclusions about lease identification, lease classification and initial direct costs. The Company also elected the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use assets based on all facts and circumstances through the effective date of the new standard. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize right-of-use assets or lease liabilities for those leases that qualify as a short-term lease (leases with lease terms of 12 months or less), which includes not recognizing right-of-use assets or lease liabilities for existing short-term leases in transition. The Company also has elected the practical expedient to avoid separating lease and non-lease components for any of its leases within its existing classes of assets. We recognize each new lease within right-of-use assets and lease liabilities once the lease commences. The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December 31, 2021, the Company incurred $20.7 million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $3.2 million was variable lease expense, which was not included in the measurement of the Company's operating right-of-use assets and lease liabilities. The variable rent expense is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company's election to not separate lease and non-lease components. For the transition period ended December 31, 2020, the Company incurred $9.9 million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $1.8 million was variable lease expense and $0.1 million was short-term lease expense, neither of which were included in the measurement of the Company's operating right-of-use assets and lease liabilities. For the year ended June 30, 2020, the Company incurred $18.4 million in lease costs, of which $2.6 million was variable lease expense and $0.2 million was short-term lease expense. Prior to the adoption of the lease guidance in ASU 2016-02, the Company's total rent expense for the year ended June 30, 2019 was $19.7 million. In December 2021, the Company entered into a non-cancelable operating lease for approximately 63,000 square feet in South San Francisco, California, which will expire in 2033. The lease will commence in April 2023. As of December 31, 2021, the maturities of the Company’s operating lease liabilities were as follows (in millions): Year Ended: 2022 $ 17.4 2023 19.8 2024 22.4 2025 16.6 2026 14.7 Thereafter 88.1 Total future lease payments 179.0 Less: amounts representing interest (27.9) Present value of future lease payments 151.1 Less: leases not yet commenced (58.8) Less: current maturities of operating lease liabilities (13.0) Noncurrent operating lease liabilities $ 79.3 As of December 31, 2021, the weighted average remaining lease term is 8.7 years and the weighted average discount rate used to determine the operating lease liability was 5.10%. As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company’s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term.

Employee Deferred Savings Plan

Employee Deferred Savings Plan	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Employee Deferred Savings Plan	EMPLOYEE DEFERRED SAVINGS PLAN The Company has a deferred savings plan which qualifies under Section 401(k) of the Internal Revenue Code. Substantially all of the Company’s U.S. employees are covered by the plan. The Company makes matching contributions of 50% of each employee’s contribution with the employer’s contribution not to exceed 4% of the employee’s compensation. The Company’s recorded contributions to the plan are as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Deferred savings plan contributions $ 8.4 $ 4.0 $ 7.1 $ 8.3

Segment and Related Information

Segment and Related Information	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment and Related Information	SEGMENT AND RELATED INFORMATION The Company’s business is aligned with how the chief operating decision maker ("CODM") reviews performance and makes decisions in managing the Company. On July 1, 2021, the Company completed the divestiture of Myriad RBM, Inc., and, as a result, now operates a single reporting segment. Prior to the sale, the Myriad RBM, Inc. operating segment was included in the Company’s previously reported other segment. The Company’s remaining operating segments have been aggregated into a single reporting segment, which primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression, and includes corporate services such as finance, human resources, legal and information technology. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. The CODM evaluates segment performance based on operating income (loss). The following table reconciles assets by geographical region to total assets: December 31, (in millions) 2021 2020 Net equipment, leasehold improvements and property: United States $ 41.7 $ 38.4 Rest of world 1.9 2.3 Total $ 43.6 $ 40.7 Total assets: United States $ 870.8 $ 1,190.3 Rest of world 51.1 56.8 Total $ 921.9 $ 1,247.1 Cash, cash equivalents, and marketable investment 398.8 171.7 Total $ 1,320.7 $ 1,418.8

Divestitures

Divestitures	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	DIVESTITURES On May 28, 2021, the Company completed the sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for cash consideration of $32.5 million. The transaction was accounted for as a sale of assets and the Company recognized a gain of $31.2 million, net of transaction costs of $1.3 million, in Other income (expense) on the Company’s Consolidated Statements of Operations. On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., then a wholly owned subsidiary of the Company, to IQVIA RDS, Inc., for cash consideration of $197.0 million. The transaction was accounted for as a sale of a business and the Company recognized a gain of $121.0 million, net of transaction costs of $4.8 million, in Other income (expense) on the Company's Consolidated Statements of Operations. On September 13, 2021, the Company completed the sale of select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit to Laboratory Corporation of America Holdings for cash consideration of $150.0 million. The transaction was accounted for as a sale of a business and the Company recognized a loss of $0.6 million, net of transaction costs of $4.4 million, in Other income (expense) on the Company's Consolidated Statements of Operations. The operating results of these businesses do not qualify for reporting as discontinued operations. Inventory In connection with the divestiture transactions, the Company recognized losses of $5.2 million and $6.5 million for a non-cancelable inventory purchase commitment and inventory, respectively, during the year ended December 31, 2021, as t he Company no longer had use for the goods. Both of these losses are included in Other income (expense) in the Company's Consolidated Statements of Operations for the year ended December, 2021. The following table details the amounts recognized in Other income for the year ended December 31, 2021: (in millions) Year Ended December 31, 2021 Gain on sale of Myriad RBM, Inc. 121.0 Gain on sale of the Myriad myPath, LLC laboratory 31.2 Loss on inventory (11.7) Loss on sale of Myriad Autoimmune assets (0.6) Other (0.6) Total Other Income $ 139.3

Business Acquisitions

Business Acquisitions	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Business Acquisitions	BUSINESS ACQUISITIONS Counsyl On July 31, 2018, the Company completed the acquisition of Counsyl, Inc. (“Counsyl”), a leading provider of genetic testing and DNA analysis services, pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated May 25, 2018 for total consideration of $405.9 million. Pursuant to the terms of the Merger Agreement, Myriad Merger Sub, Inc., a newly created wholly-owned subsidiary of the Company, was merged with and into Counsyl, with Counsyl continuing as the surviving corporation and a wholly-owned subsidiary of Myriad. To complete the purchase transaction, the Company incurred approximately $6.8 million of acquisition costs, which are recorded as selling, general and administrative expenses in the period incurred. For the year ended June 30, 2019, Counsyl contributed revenue of approximately $104.9 million. For the year ended June 30, 2019, operating expenses related to Counsyl were approximately $67.6 million.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Event	SUBSEQUENT EVENTIn the first quarter of 2022, the Company entered into a non-cancelable operating lease for approximately 230,000 square feet in Salt Lake City, Utah, which will commence in 2022, with a lease term of 15 years and total future lease payments of approximately $77.8 million.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	SUPPLEMENTAL CASH FLOW INFORMATION Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Cash paid for income taxes $ 4.6 $ 1.8 $ 1.0 $ 6.5 Cash paid for interest 4.4 5.2 9.5 11.6 Cash received for income tax receivables 90.0 — — — Non-cash investing and financing activities: Establishment of operating lease right-of-use assets and lease liabilities Operating lease right-of-use assets $ 41.8 $ — $ 74.5 $ — Operating lease liabilities (48.1) — (78.8) — Accrued liabilities and other long-term liabilities — — 4.3 —

Transition Period Comparative D

Transition Period Comparative Data (Unaudited)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Transition Period Comparative Data (Unaudited)	TRANSITION PERIOD COMPARATIVE DATA (UNAUDITED) (in millions) Year Ended Six-month Consolidated Statement of Operations Data: December 31, 2020 December 31, 2019 Molecular diagnostic testing $ 513.5 $ 353.1 Pharmaceutical and clinical services 43.6 28.3 Total revenue 557.1 381.4 Costs and expenses: Cost of molecular diagnostic testing 157.9 82.2 Cost of pharmaceutical and clinical services 20.3 17.1 Research and development expense 73.3 40.1 Selling, general and administrative expense 496.9 270.4 Goodwill and long-lived asset impairment charges 98.4 1.3 Total costs and expenses 846.8 411.1 Operating loss (289.7) (29.7) Other income (expense): Interest income 2.0 1.7 Interest expense (11.2) (5.4) Other 15.3 (0.3) Total other income (expense) 6.1 (4.0) Loss before income taxes (283.6) (33.7) Income tax benefit (59.9) (4.8) Net loss (223.7) (28.9) Net loss attributable to non-controlling interest (0.1) — Net loss attributable to Myriad Genetics Inc. stockholders $ (223.6) $ (28.9) Loss per share: Basic $ (2.99) $ (0.39) Diluted $ (2.99) $ (0.39) Weighted average shares outstanding: Basic 74.8 74.1 Diluted 74.8 74.1

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Financial Statement Presentation	Basis of Financial Statement Presentation Myriad Genetics, Inc. and subsidiaries (collectively, the "Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical specialties. The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters are located in Salt Lake City, Utah.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in accordance with GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, cash flows from operations, or net loss for the period.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s account receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 17%, 16%, 15% and 14% of total revenue for the year ended December 31, 2021, the six-month transition period ended December 31, 2020 and the years ended June 30, 2020 and 2019, respectively. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. No customer accounted for more than 10% of accounts receivable at December 31, 2021 or December 31, 2020.
Cash and Cash Equivalents	Cash and Cash EquivalentsThe Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions.
Marketable Investment Securities	Marketable Investment Securities The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company’s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash. A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company’s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the year ended December 31, 2021, the transition period ended December 31, 2020 or during the years ended June 30, 2020 and 2019.
Inventory	Inventory Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis. In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company evaluates its inventories for excess quantities and obsolescence. Inventories that are considered excess or obsolete are expensed. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management’s assessment of current and expected orders from the Company’s customers.
Trade Accounts Receivable	Trade Accounts Receivable Trade accounts receivable represents amounts billed to customers for revenue recognized related to molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 16, pharmaceutical and clinical services. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.
Property, Plant and Equipment	Property, Plant and Equipment Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of five one
Intangible Assets and Other Long-Lived Assets	Intangible Assets and Other Long-Lived Assets Intangible and other long-lived assets are comprised of acquired licenses and technology and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The classification of the Company’s acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December 31, 2021 and 2020, the Company had unamortized software costs of $6.7 million and $2.3 million, respectively. For the year ended December 31, 2021, amortization expense for capitalized software costs was $0.2 million. There was no capitalized software amortization expense for the remaining periods presented. The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Goodwill	Goodwill Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill is first assessed using a qualitative approach. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed. The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.
Revenue Recognition	Revenue Recognition Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the "Clinic") in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. See Note 16 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of clinical and pharmaceutical services indicates transfer of control for revenue recognition purposes. The following table represents the Company’s revenue by type for the year ended December 31, 2021, the transition period ended December 31, 2020, and the years ended June 30, 2020 and 2019: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (In millions) 2021 2020 2020 2019 Molecular diagnostic revenues: Hereditary Cancer $ 316.3 $ 159.3 $ 347.4 $ 479.7 Tumor Profiling 120.9 33.9 48.3 43.0 Prenatal 106.8 37.6 76.7 104.9 Pharmacogenomics 93.7 29.8 74.1 112.6 Autoimmune 28.2 18.0 39.1 48.3 Other 0.5 1.0 1.3 0.9 Total molecular diagnostic revenue 666.4 279.6 586.9 789.4 Pharmaceutical and clinical service revenue 24.2 20.2 51.7 61.7 Total revenue $ 690.6 $ 299.8 $ 638.6 $ 851.1 In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue: Year Ended Six-month Transition Period Ended December 31, 2021 2020 (in millions) U.S. RoW Total U.S. RoW Total Molecular diagnostic revenues: Hereditary Cancer $ 271.0 $ 45.3 $ 316.3 $ 140.9 $ 18.4 $ 159.3 Tumor Profiling 80.4 40.5 120.9 28.2 5.7 33.9 Prenatal 106.2 0.6 106.8 37.4 0.2 37.6 Pharmacogenomics 93.7 — 93.7 29.8 — 29.8 Autoimmune 28.2 — 28.2 18.0 — 18.0 Other — 0.5 0.5 1.0 — 1.0 Total molecular diagnostic revenue 579.5 86.9 666.4 255.3 24.3 279.6 Pharmaceutical and clinical services revenue 24.2 — 24.2 20.1 0.1 20.2 Total revenue $ 603.7 $ 86.9 $ 690.6 $ 275.4 $ 24.4 $ 299.8 Year Ended June 30, 2020 2019 (in millions) U.S. RoW Total U.S. RoW Total Molecular diagnostic revenues: Hereditary Cancer $ 329.8 $ 17.6 $ 347.4 $ 466.7 $ 13.0 $ 479.7 Tumor Profiling 39.2 9.1 48.3 34.6 8.4 43.0 Prenatal 76.4 0.3 76.7 104.9 — 104.9 Pharmacogenomics 74.1 — 74.1 112.6 — 112.6 Autoimmune 39.1 — 39.1 48.3 — 48.3 Other 1.2 0.1 1.3 0.5 0.4 0.9 Total molecular diagnostic revenue 559.8 27.1 586.9 767.6 21.8 789.4 Pharmaceutical and clinical services revenue 36.4 15.3 51.7 37.8 23.9 61.7 Total revenue $ 596.2 $ 42.4 $ 638.6 $ 805.4 $ 45.7 $ 851.1 Under ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally customers make payments prior to the Company's performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During the year ended June 30, 2020, the Company received approximat ely $29.7 million in a dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Deferred revenue - beginning balance $ 32.7 $ 32.8 $ 2.2 $ 2.6 Revenue recognized (40.5) (6.1) (7.2) (7.9) Prepayments 14.0 6.0 37.8 7.5 Divestitures (1.0) — — — Deferred revenue - ending balance $ 5.2 $ 32.7 $ 32.8 $ 2.2 In accordance with Topic 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that are constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of request for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Consolidated Statements of Operations and Comprehensive Income (Loss). Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December 31, 2021, the Company recognized $15.9 million in revenue which resulted in a $0.15 impact to earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December 31, 2021, revenue of $6.8 million was recognized due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period. During the year ended June 30, 2020, the Company recognized a $9.9 million decrease in revenue, which resulted in a $(0.10) impact to earnings (loss) per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the year ended June 30, 2020 resulted in an impact to earnings (loss) per share for the year ended June 30, 2020 of $(0.05). During the transition period ended December 31, 2020, and year ended June 30, 2019, the impact to revenue and earnings (loss) per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. In accordance with Topic 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, etc. The Company has elected to apply the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company has also elected to apply the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payments terms have a payback period of less than one year.
Stock-based Payment Expense	Stock-based Payment Expense We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with Accounting Standards Codification (“ASC”) 718, Compensation – Stock Compensation. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee’s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company’s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Simulation model. For PSUs, t he Company estimates the likelihood of achievement of the performance conditions at the end of each period. Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of our stock price.
Other Income (Expense)	Other Income (Expense)The Company recognizes the gain or loss on its divestitures as Other income (expense). During the years ended December 31, 2021 and June 30, 2020, the Company recognized a net gain on divestitures of $162.0 million and $1.0 million, respectively. See Note 16 for additional information regarding these divestitures. In addition, during the year ended June 30, 2020, the Company received approximately $14.6 million, respectively, from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that are attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations.
Income Taxes	Income Taxes The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company’s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows.
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Denominator: Weighted-average shares outstanding used to compute 78.0 75.0 74.3 73.5 Effect of dilutive stock options — — — 2.5 Weighted-average shares outstanding and dilutive 78.0 75.0 74.3 76.0 Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Anti-dilutive options and RSUs excluded from EPS computation 4.5 6.6 5.5 0.8
Foreign Currency	Foreign Currency The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive income (loss) as a separate component of Stockholders’ equity. The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions): Ending balance December 31, 2020 $ (3.1) Period translation adjustments (1.8) Ending balance December 31, 2021 $ (4.9)
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Standards In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for public companies with fiscal years beginning after December 15, 2020, with early adoption permitted. The guidance was adopted with no material impact to the Company's consolidated financial statements.
Fair Value Measurements	The fair value of the Company’s financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2— observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities. Level 3—unobservable inputs. All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the contingent consideration period of approximately 13.5 years, utilizing various potential pay-out scenarios. Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business. The contingent consideration liabilities are classified as a component of Accrued liabilities and Other long-term liabilities in the Company’s Consolidated Balance Sheets. Changes to the contingent consideration liabilities are reflected in Selling, general, and administrative expense in our Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements.

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Revenue by Type	The following table represents the Company’s revenue by type for the year ended December 31, 2021, the transition period ended December 31, 2020, and the years ended June 30, 2020 and 2019: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (In millions) 2021 2020 2020 2019 Molecular diagnostic revenues: Hereditary Cancer $ 316.3 $ 159.3 $ 347.4 $ 479.7 Tumor Profiling 120.9 33.9 48.3 43.0 Prenatal 106.8 37.6 76.7 104.9 Pharmacogenomics 93.7 29.8 74.1 112.6 Autoimmune 28.2 18.0 39.1 48.3 Other 0.5 1.0 1.3 0.9 Total molecular diagnostic revenue 666.4 279.6 586.9 789.4 Pharmaceutical and clinical service revenue 24.2 20.2 51.7 61.7 Total revenue $ 690.6 $ 299.8 $ 638.6 $ 851.1
Schedule of Revenue by Geographical Region	In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue: Year Ended Six-month Transition Period Ended December 31, 2021 2020 (in millions) U.S. RoW Total U.S. RoW Total Molecular diagnostic revenues: Hereditary Cancer $ 271.0 $ 45.3 $ 316.3 $ 140.9 $ 18.4 $ 159.3 Tumor Profiling 80.4 40.5 120.9 28.2 5.7 33.9 Prenatal 106.2 0.6 106.8 37.4 0.2 37.6 Pharmacogenomics 93.7 — 93.7 29.8 — 29.8 Autoimmune 28.2 — 28.2 18.0 — 18.0 Other — 0.5 0.5 1.0 — 1.0 Total molecular diagnostic revenue 579.5 86.9 666.4 255.3 24.3 279.6 Pharmaceutical and clinical services revenue 24.2 — 24.2 20.1 0.1 20.2 Total revenue $ 603.7 $ 86.9 $ 690.6 $ 275.4 $ 24.4 $ 299.8 Year Ended June 30, 2020 2019 (in millions) U.S. RoW Total U.S. RoW Total Molecular diagnostic revenues: Hereditary Cancer $ 329.8 $ 17.6 $ 347.4 $ 466.7 $ 13.0 $ 479.7 Tumor Profiling 39.2 9.1 48.3 34.6 8.4 43.0 Prenatal 76.4 0.3 76.7 104.9 — 104.9 Pharmacogenomics 74.1 — 74.1 112.6 — 112.6 Autoimmune 39.1 — 39.1 48.3 — 48.3 Other 1.2 0.1 1.3 0.5 0.4 0.9 Total molecular diagnostic revenue 559.8 27.1 586.9 767.6 21.8 789.4 Pharmaceutical and clinical services revenue 36.4 15.3 51.7 37.8 23.9 61.7 Total revenue $ 596.2 $ 42.4 $ 638.6 $ 805.4 $ 45.7 $ 851.1
Reconciliation of Deferred Revenue Balances	A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Deferred revenue - beginning balance $ 32.7 $ 32.8 $ 2.2 $ 2.6 Revenue recognized (40.5) (6.1) (7.2) (7.9) Prepayments 14.0 6.0 37.8 7.5 Divestitures (1.0) — — — Deferred revenue - ending balance $ 5.2 $ 32.7 $ 32.8 $ 2.2
Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations	The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Denominator: Weighted-average shares outstanding used to compute 78.0 75.0 74.3 73.5 Effect of dilutive stock options — — — 2.5 Weighted-average shares outstanding and dilutive 78.0 75.0 74.3 76.0
Schedule of Potential Dilutive Common Shares	These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Anti-dilutive options and RSUs excluded from EPS computation 4.5 6.6 5.5 0.8
Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss	The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions): Ending balance December 31, 2020 $ (3.1) Period translation adjustments (1.8) Ending balance December 31, 2021 $ (4.9)

Marketable Investment Securit_2

Marketable Investment Securities (Tables)	12 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security	The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December 31, 2021 and December 31, 2020 were as follows: (in millions) Amortized Gross Gross Estimated December 31, 2021: Cash and cash equivalents: Cash $ 195.2 $ — $ — $ 195.2 Cash equivalents 63.2 — — 63.2 Total cash and cash equivalents 258.4 — — 258.4 Available-for-sale: Corporate bonds and notes 105.7 0.1 (0.2) 105.6 Municipal bonds 16.1 — — 16.1 Federal agency issues 6.8 — — 6.8 US government securities 11.9 — — 11.9 Total $ 398.9 $ 0.1 $ (0.2) $ 398.8 (in millions) Amortized Gross Gross Estimated December 31, 2020: Cash and cash equivalents: Cash $ 47.9 $ — $ — $ 47.9 Cash equivalents 69.1 — — 69.1 Total cash and cash equivalents 117.0 — — 117.0 Available-for-sale: Corporate bonds and notes 28.8 0.5 — 29.3 Municipal bonds 9.4 0.2 — 9.6 Federal agency issues 4.0 — — 4.0 US government securities 11.7 0.1 — 11.8 Total $ 170.9 $ 0.8 $ — $ 171.7
Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December 31, 2021: (in millions) Amortized Estimated Cash 195.2 195.2 Cash equivalents 63.2 63.2 Available-for-sale: Due within one year 80.3 80.4 Due after one year through five years 60.2 60.0 Due after five years — — Total $ 398.9 $ 398.8

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities	The following tables set forth the fair value of the Company’s financial assets and liabilities that are re-measured on a regular basis: (in millions) Level 1 Level 2 Level 3 Total December 31, 2021 Money market funds (a) $ 63.2 $ — $ — $ 63.2 Corporate bonds and notes — 105.6 — 105.6 Municipal bonds — 16.1 — 16.1 Federal agency issues — 6.8 — 6.8 US government securities — 11.9 — 11.9 Contingent consideration — — (8.6) (8.6) Total $ 63.2 $ 140.4 $ (8.6) $ 195.0 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. (in millions) Level 1 Level 2 Level 3 Total December 31, 2020 Money market funds (a) $ 69.1 $ — $ — $ 69.1 Corporate bonds and notes — 29.3 — 29.3 Municipal bonds — 9.6 — 9.6 Federal agency issues — 4.0 — 4.0 US government securities — 11.8 — 11.8 Contingent consideration — — (10.9) (10.9) Total $ 69.1 $ 54.7 $ (10.9) $ 112.9 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest.
Change in Fair Value of Contingent Consideration	The following table reconciles the change in the fair value of the contingent consideration during the periods presented: (in millions) Year Ended December 31, 2021 Transition Period Ended December 31, 2020 Year Ended June 30, 2020 Year Ended June 30, 2019 Carrying amount at beginning of period $ 10.9 $ 6.8 $ 13.8 $ 14.5 Payment of contingent consideration (3.3) (0.1) (3.9) — Change in fair value recognized in the statement of operations 1.8 3.5 (2.8) (1.1) Translation adjustments recognized in other comprehensive income (loss) (0.8) 0.7 (0.3) 0.4 Carrying amount at end of period $ 8.6 $ 10.9 $ 6.8 $ 13.8

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	December 31, (in millions) 2021 2020 Leasehold improvements 38.0 35.7 Equipment 112.4 117.9 Property, plant and equipment, gross 150.4 153.6 Less accumulated depreciation (106.9) (112.9) Property, plant and equipment, net $ 43.5 $ 40.7 Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Depreciation expense $ 12.1 $ 5.0 $ 11.0 $ 13.7

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the year ended December 31, 2021 is as follows: (in millions) Year Ended December 31, 2021 Beginning balance $ 329.2 Divestitures (88.5) Translation adjustments (1.5) Carrying amount at end of period $ 239.2
Schedule of Amortizable Intangible Assets	The following tables summarize the amounts reported as intangible assets (in millions): At December 31, 2021: Gross Accumulated Amortization Net Purchased licenses and technologies $ 616.6 $ (212.5) $ 404.1 Total intangible assets $ 616.6 $ (212.5) $ 404.1 At December 31, 2020: Gross Accumulated Amortization Net Purchased licenses and technologies $ 818.2 $ (248.2) $ 570.0 Customer relationships 4.7 (4.5) 0.2 Trademarks 3.0 (1.5) 1.5 Total amortizable intangible assets 825.9 (254.2) 571.7 In-process research and development 4.8 — 4.8 Total unamortized intangible assets 4.8 — 4.8 Total intangible assets $ 830.7 $ (254.2) $ 576.5
Schedule of Non-amortizable Intangible Assets	The following tables summarize the amounts reported as intangible assets (in millions): At December 31, 2021: Gross Accumulated Amortization Net Purchased licenses and technologies $ 616.6 $ (212.5) $ 404.1 Total intangible assets $ 616.6 $ (212.5) $ 404.1 At December 31, 2020: Gross Accumulated Amortization Net Purchased licenses and technologies $ 818.2 $ (248.2) $ 570.0 Customer relationships 4.7 (4.5) 0.2 Trademarks 3.0 (1.5) 1.5 Total amortizable intangible assets 825.9 (254.2) 571.7 In-process research and development 4.8 — 4.8 Total unamortized intangible assets 4.8 — 4.8 Total intangible assets $ 830.7 $ (254.2) $ 576.5
Schedule of Recorded Amortization for Intangible Assets	The Company recorded amortization during the respective periods for these intangible assets as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Amortization of intangible assets $ 50.7 $ 30.8 $ 61.0 $ 59.3
Schedule of Future Amortization Expense of Intangible Assets	Future amortization expense of intangible assets as of December 31, 2021 is estimated to be as follows (in millions): Years Ended December 31, Amortization Expense 2022 $ 40.8 2023 40.8 2024 40.8 2025 40.8 2026 40.8 Thereafter 200.1 Total $ 404.1

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Summary of Accrued Liabilities	December 31, (in millions) 2021 2020 Employee compensation and benefits $ 52.8 $ 48.9 Legal charges pending settlement 62.0 — Accrued taxes payable 4.0 4.3 Refunds payable and reserves 9.8 9.3 Short-term contingent consideration 3.2 3.4 Accrued royalties 5.4 3.8 Other accrued liabilities 19.3 9.4 Total accrued liabilities $ 156.5 $ 79.1

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Summary of Other Long-Term Liabilities	December 31, (in millions) 2021 2020 Contingent consideration $ 5.4 $ 7.4 Other 0.2 7.3 Total other long-term liabilities $ 5.6 $ 14.7

Preferred and Common Stockhol_2

Preferred and Common Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Summary of Common Shares Issued and Outstanding	Common shares issued and outstanding Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Beginning common stock issued and outstanding 75.4 74.7 73.5 70.6 Common stock issued upon exercise of options and employee stock plans 4.6 0.7 1.2 4.5 Repurchase and retirement of common stock — — — (1.6) Ending common stock issued and outstanding 80.0 75.4 74.7 73.5
Schedule of Stock Repurchases	The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to Retained earnings (accumulated deficit) for the repurchases for periods ended December 31, 2021, December 31, 2020, June 30, 2020, and June 30, 2019 were as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Shares purchased and retired — — — 1.6 Common stock and additional paid-in-capital reductions $ — $ — $ — $ 16.9 Charges to retained earnings $ — $ — $ — $ 33.1

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of option activity under the Company's equity plans, including the Company's inducement awards, is as follows for the year ended December 31, 2021: (number of shares in millions) Number Weighted Weighted Options outstanding at beginning of period 5.2 $ 23.24 Options granted — — Less: Options exercised (3.7) 24.26 Options canceled or expired (0.1) 25.18 Options outstanding at end of period 1.4 20.36 3.08 Options exercisable at end of period 1.0 23.07 2.09 Options vested and expected to vest 1.4 20.36 3.08
Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding at December 31, 2021 (number of shares in millions): Options outstanding Range of Number outstanding at December 31, Weighted Weighted $13.38 0.7 5.62 $ 13.38 $23.98 0.1 0.18 23.98 $27.07 - 36.55 0.6 0.74 27.25 1.4 3.08 $ 20.38
Schedule of Restricted Stock Units Activity	A summary of the RSU activity under the Company's equity plans, including the Company's inducement awards and RSU awards with performance metrics, is as follows for the year ended December 31, 2021: 2021 (number of shares in millions) Number Weighted RSUs unvested and outstanding at beginning of period 3.2 $ 20.56 RSUs granted 1.8 29.83 Less: RSUs vested (1.1) 21.32 RSUs canceled (0.8) 24.48 RSUs unvested and outstanding at end of period 3.1 $ 24.96
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Cost of molecular diagnostic testing $ 1.5 $ 0.6 $ 1.2 $ 0.8 Cost of pharmaceutical and clinical services 0.1 0.1 0.3 0.2 Research and development expense 4.2 2.4 5.0 5.4 Selling, general, and administrative expense 30.5 11.8 18.7 27.1 Total stock-based compensation expense $ 36.3 $ 14.9 $ 25.2 $ 33.5
Schedule of Aggregate Intrinsic Value	The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows: (in millions) As of Aggregate intrinsic value of options outstanding $ 10.2 Aggregate intrinsic value of options fully vested 4.6 Aggregate intrinsic value of RSUs outstanding 86.3
Schedule of Intrinsic Value of Options Exercised	The total intrinsic value of options exercised was as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Total intrinsic value of options exercised $ 29.2 $ 0.5 $ 8.8 $ 0.4
Schedule of Shares Purchased and Compensation Expenses for ESPP	Shares purchased under and compensation expense associated with the 2012 Purchase Plan for the years reported are as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Shares purchased under the plans 0.2 0.1 0.3 0.2 Plan compensation expense $ 1.5 $ 0.6 $ 1.7 $ 1.0
Schedule of Valuation Assumptions for ESPP	The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black‑Scholes option-pricing model using the following weighted-average assumptions: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, 2021 2020 2020 2019 Risk-free interest rate 0.1% 0.2% 1.8% 2.1% Expected dividend yield —% —% —% —% Expected life (in years) 0.5 0.5 0.5 0.5 Expected volatility 60% 94% 99% 55%

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Income Tax Benefit	Income tax benefit consists of the following: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Current: Federal $ (1.9) $ (75.8) $ 26.6 $ (24.2) State 3.6 (0.6) 4.9 (0.1) Foreign 0.1 0.2 0.5 0.2 Total current 1.8 (76.2) 32.0 (24.1) Deferred: Federal (33.7) 39.1 (51.5) 17.8 State 5.1 (3.4) (4.1) 1.7 Foreign 0.1 (0.5) (3.6) 0.4 Change in valuation allowance (3.2) — 3.5 (0.2) Total deferred (31.7) 35.2 (55.7) 19.7 Total income tax benefit $ (29.9) $ (41.0) $ (23.7) $ (4.4)
Schedule of Income (Loss) Before Income Taxes	Income (loss) before income taxes consists of the following: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 United States $ (53.8) $ (101.8) $ (240.9) $ (0.6) Foreign (3.3) 7.7 17.6 0.6 Total $ (57.1) $ (94.1) $ (223.3) $ —
Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported	The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Federal income tax expense at the statutory rate $ (12.0) 21.0 % $ (19.8) 21.0 % $ (46.9) 21.0 % $ — 21.0 % State income taxes, net of federal benefit (1.8) 3.2 % (1.2) 1.3 % 4.0 (1.8) % 2.0 6,422.1 % Research and development credits 2.5 (4.4) % (1.3) 1.4 % (2.8) 1.3 % (3.7) (11,880.9) % Uncertain tax positions (3.0) 5.3 % 0.6 (0.7) % 1.5 (0.7) % (4.2) (13,486.4) % Incentive stock option and employee stock purchase plan expense 0.7 (1.2) % 2.5 (2.7) % (0.2) 0.1 % (3.1) (9,954.3) % Foreign rate differential 0.5 (0.9) % (2.1) 2.2 % 0.7 (0.3) % 0.8 2,568.8 % Change in valuation allowance (3.2) 5.6 % (0.3) 0.3 % 3.5 (1.7) % (0.2) (642.2) % CARES Act 2.7 (4.7) % (20.7) 22.0 % — — % — — % Non-deductible meals and entertainment 0.1 (0.2) % 0.5 (0.5) % 1.8 (0.8) % 1.3 4,174.4 % Non-deductible officer compensation 3.3 (5.8) % 0.1 (0.1) % 1.6 (0.7) % 0.6 1,926.6 % Asset impairment — — % — — % 12.6 (5.6) % — — % Non-deductible legal settlement 2.5 (4.5) % — — % — — % 1.9 6,101.0 % Acquisitions, Dispositions, and Contingent Consideration (23.0) 40.3 % 0.7 (0.7) % (0.3) 0.1 % 0.8 2,568.8 % Method changes or tax elections — — % — — % — — % (0.9) (2,890.0) % Other, net 0.8 (1.4) % — — % 0.8 (0.3) % 0.3 963.4 % Total income tax benefit $ (29.9) 52.3 % $ (41.0) 43.5 % $ (23.7) 10.6 % $ (4.4) -14,107.7 %
Schedule of Components of Deferred Tax Assets and Liabilities	The significant components of the Company’s deferred tax assets and liabilities were comprised of the following: December 31, (in millions) 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 67.2 $ 72.2 Deferred revenue 1.2 7.2 Stock compensation expense 4.5 11.5 Research and development credits 17.3 24.9 Lease right-of-use asset 22.4 15.2 Accrued expenses and liabilities 14.2 7.6 Other, net 4.5 6.4 Total gross deferred tax assets 131.3 145.0 Less valuation allowance (38.5) (42.0) Total deferred tax assets 92.8 103.0 Deferred tax liabilities: Intangible assets 104.9 144.0 Lease liability 20.2 14.6 Property, plant and equipment 3.5 15.7 Total deferred tax liabilities 128.6 174.3 Net deferred tax liability $ (35.8) $ (71.3)
Schedule of Net Operating Loss and Research Credit Carryforwards (Tax Effected)	At December 31, 2021, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions): Carryforwards Amount Subject to Expires Through Federal net operating loss $ 31.2 Yes 2036 2037 Federal capital loss 13.5 No 2026 2026 Utah net operating loss 2.4 No 2022 Indefinite California net operating loss 3.9 Yes 2027 2042 Other state net operating loss 7.4 Yes 2027 2041 Foreign net operating losses (various jurisdictions) 8.8 No Various Various Federal research credit 6.4 Yes 2027 2042 Utah research credit 6.9 No 2022 2036 California research credit 4.0 No Indefinite Indefinite
Schedule of Unrecognized Tax Benefits	The Company’s gross unrecognized tax benefits as of the year ended December 31, 2021, the transition period ended December 31, 2020 and the years ended June 30, 2020 and 2019, and the changes in those balances are as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Unrecognized tax benefits at the beginning of period $ 37.6 $ 23.5 $ 21.7 $ 24.9 Gross increases - current year tax positions 1.4 13.9 1.6 2.2 Gross increases - prior year tax positions 1.1 1.0 0.7 0.5 Gross increases - acquisitions — — — 2.3 Gross decreases - prior year tax positions (2.8) (0.1) — (0.1) Gross decreases - settlements (5.1) — — (2.7) Gross decreases - statute lapse (0.1) (0.7) (0.5) (5.4) Unrecognized tax benefits at end of year $ 32.1 $ 37.6 $ 23.5 $ 21.7 Interest and penalties in year-end balance $ 3.3 $ 2.2 $ 1.4 $ 0.8

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of Maturities of Operating Lease Liabilities	As of December 31, 2021, the maturities of the Company’s operating lease liabilities were as follows (in millions): Year Ended: 2022 $ 17.4 2023 19.8 2024 22.4 2025 16.6 2026 14.7 Thereafter 88.1 Total future lease payments 179.0 Less: amounts representing interest (27.9) Present value of future lease payments 151.1 Less: leases not yet commenced (58.8) Less: current maturities of operating lease liabilities (13.0) Noncurrent operating lease liabilities $ 79.3

Employee Deferred Savings Plan

Employee Deferred Savings Plan (Tables)	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Schedule of Contributions to the Plan	The Company’s recorded contributions to the plan are as follows: Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Deferred savings plan contributions $ 8.4 $ 4.0 $ 7.1 $ 8.3

Segment and Related Informati_2

Segment and Related Information (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Schedule of Assets by Geographical Region	The following table reconciles assets by geographical region to total assets: December 31, (in millions) 2021 2020 Net equipment, leasehold improvements and property: United States $ 41.7 $ 38.4 Rest of world 1.9 2.3 Total $ 43.6 $ 40.7 Total assets: United States $ 870.8 $ 1,190.3 Rest of world 51.1 56.8 Total $ 921.9 $ 1,247.1 Cash, cash equivalents, and marketable investment 398.8 171.7 Total $ 1,320.7 $ 1,418.8

Divestitures (Tables)

Divestitures (Tables)	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Amounts Recognized in Other Income	The following table details the amounts recognized in Other income for the year ended December 31, 2021: (in millions) Year Ended December 31, 2021 Gain on sale of Myriad RBM, Inc. 121.0 Gain on sale of the Myriad myPath, LLC laboratory 31.2 Loss on inventory (11.7) Loss on sale of Myriad Autoimmune assets (0.6) Other (0.6) Total Other Income $ 139.3

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	Year Ended December 31, Six-month Transition Period Ended December 31, Years Ended June 30, (in millions) 2021 2020 2020 2019 Cash paid for income taxes $ 4.6 $ 1.8 $ 1.0 $ 6.5 Cash paid for interest 4.4 5.2 9.5 11.6 Cash received for income tax receivables 90.0 — — — Non-cash investing and financing activities: Establishment of operating lease right-of-use assets and lease liabilities Operating lease right-of-use assets $ 41.8 $ — $ 74.5 $ — Operating lease liabilities (48.1) — (78.8) — Accrued liabilities and other long-term liabilities — — 4.3 —

Transition Period Comparative_2

Transition Period Comparative Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Transition Period Comparative Data	(in millions) Year Ended Six-month Consolidated Statement of Operations Data: December 31, 2020 December 31, 2019 Molecular diagnostic testing $ 513.5 $ 353.1 Pharmaceutical and clinical services 43.6 28.3 Total revenue 557.1 381.4 Costs and expenses: Cost of molecular diagnostic testing 157.9 82.2 Cost of pharmaceutical and clinical services 20.3 17.1 Research and development expense 73.3 40.1 Selling, general and administrative expense 496.9 270.4 Goodwill and long-lived asset impairment charges 98.4 1.3 Total costs and expenses 846.8 411.1 Operating loss (289.7) (29.7) Other income (expense): Interest income 2.0 1.7 Interest expense (11.2) (5.4) Other 15.3 (0.3) Total other income (expense) 6.1 (4.0) Loss before income taxes (283.6) (33.7) Income tax benefit (59.9) (4.8) Net loss (223.7) (28.9) Net loss attributable to non-controlling interest (0.1) — Net loss attributable to Myriad Genetics Inc. stockholders $ (223.6) $ (28.9) Loss per share: Basic $ (2.99) $ (0.39) Diluted $ (2.99) $ (0.39) Weighted average shares outstanding: Basic 74.8 74.1 Diluted 74.8 74.1

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Other-than-temporary impairments	$ 0		$ 0		$ 0	$ 0
Unamortized software costs	2,300,000		6,700,000	$ 2,300,000
Amortization expense for capitalized software	0		200,000		0	0
Advance Medicare payments to provide relief from economic impacts of COVID-19					29,700,000
Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments			15,900,000		9,900,000
Revenue recognized due to expanded local coverage determination for which revenue was previously constrained			6,800,000
Accrued liability for Medicare refund	9,400,000		19,300,000	9,400,000
Revenues	299,800,000	$ 381,400,000	690,600,000	$ 557,100,000	638,600,000	851,100,000
Capitalized costs incurred to obtain or fulfill contract			0
Net gain on divestiture	$ 0		$ 162,000,000		1,000,000	$ 0
Provider fund relief under CARES Act					$ 14,600,000
Immaterial prior period Medicare claims
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Change in earnings (loss) per share (dollars per share)					$ (0.05)
Accrued liability for Medicare refund					$ 4,700,000
Revenues					$ (4,700,000)
Performance obligation estimate
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Change in earnings (loss) per share (dollars per share)			$ 0.15		$ (0.10)
Equipment | Minimum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives (in years)			5 years
Equipment | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives (in years)			7 years
Leasehold improvements | Minimum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives (in years)			1 year
Leasehold improvements | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives (in years)			7 years
Government contracts concentration risk | Medicare | Revenue
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Concentration risk (percent)	16.00%		17.00%		15.00%	14.00%

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies - Revenue by Type (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenue	$ 299.8	$ 381.4	$ 690.6	$ 557.1	$ 638.6	$ 851.1
Molecular diagnostic revenues
Disaggregation of Revenue [Line Items]
Total revenue	279.6	353.1	666.4	513.5	586.9	789.4
Molecular diagnostic - Hereditary Cancer
Disaggregation of Revenue [Line Items]
Total revenue	159.3		316.3		347.4	479.7
Molecular diagnostic - Tumor Profiling
Disaggregation of Revenue [Line Items]
Total revenue	33.9		120.9		48.3	43
Molecular diagnostic - Prenatal
Disaggregation of Revenue [Line Items]
Total revenue	37.6		106.8		76.7	104.9
Molecular diagnostic - Pharmacogenomics
Disaggregation of Revenue [Line Items]
Total revenue	29.8		93.7		74.1	112.6
Molecular diagnostic - Autoimmune
Disaggregation of Revenue [Line Items]
Total revenue	18		28.2		39.1	48.3
Molecular diagnostic - Other
Disaggregation of Revenue [Line Items]
Total revenue	1		0.5		1.3	0.9
Pharmaceutical and clinical services
Disaggregation of Revenue [Line Items]
Total revenue	$ 20.2	$ 28.3	$ 24.2	$ 43.6	$ 51.7	$ 61.7

Organization and Summary of S_6

Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenue	$ 299.8	$ 381.4	$ 690.6	$ 557.1	$ 638.6	$ 851.1
Molecular diagnostic revenues
Disaggregation of Revenue [Line Items]
Total revenue	279.6	353.1	666.4	513.5	586.9	789.4
Molecular diagnostic - Hereditary Cancer
Disaggregation of Revenue [Line Items]
Total revenue	159.3		316.3		347.4	479.7
Molecular diagnostic - Tumor Profiling
Disaggregation of Revenue [Line Items]
Total revenue	33.9		120.9		48.3	43
Molecular diagnostic - Prenatal
Disaggregation of Revenue [Line Items]
Total revenue	37.6		106.8		76.7	104.9
Molecular diagnostic - Pharmacogenomics
Disaggregation of Revenue [Line Items]
Total revenue	29.8		93.7		74.1	112.6
Molecular diagnostic - Autoimmune
Disaggregation of Revenue [Line Items]
Total revenue	18		28.2		39.1	48.3
Molecular diagnostic - Other
Disaggregation of Revenue [Line Items]
Total revenue	1		0.5		1.3	0.9
Pharmaceutical and clinical services
Disaggregation of Revenue [Line Items]
Total revenue	20.2	$ 28.3	24.2	$ 43.6	51.7	61.7
United States
Disaggregation of Revenue [Line Items]
Total revenue	275.4		603.7		596.2	805.4
United States | Molecular diagnostic revenues
Disaggregation of Revenue [Line Items]
Total revenue	255.3		579.5		559.8	767.6
United States | Molecular diagnostic - Hereditary Cancer
Disaggregation of Revenue [Line Items]
Total revenue	140.9		271		329.8	466.7
United States | Molecular diagnostic - Tumor Profiling
Disaggregation of Revenue [Line Items]
Total revenue	28.2		80.4		39.2	34.6
United States | Molecular diagnostic - Prenatal
Disaggregation of Revenue [Line Items]
Total revenue	37.4		106.2		76.4	104.9
United States | Molecular diagnostic - Pharmacogenomics
Disaggregation of Revenue [Line Items]
Total revenue	29.8		93.7		74.1	112.6
United States | Molecular diagnostic - Autoimmune
Disaggregation of Revenue [Line Items]
Total revenue	18		28.2		39.1	48.3
United States | Molecular diagnostic - Other
Disaggregation of Revenue [Line Items]
Total revenue	1		0		1.2	0.5
United States | Pharmaceutical and clinical services
Disaggregation of Revenue [Line Items]
Total revenue	20.1		24.2		36.4	37.8
Rest of world
Disaggregation of Revenue [Line Items]
Total revenue	24.4		86.9		42.4	45.7
Rest of world | Molecular diagnostic revenues
Disaggregation of Revenue [Line Items]
Total revenue	24.3		86.9		27.1	21.8
Rest of world | Molecular diagnostic - Hereditary Cancer
Disaggregation of Revenue [Line Items]
Total revenue	18.4		45.3		17.6	13
Rest of world | Molecular diagnostic - Tumor Profiling
Disaggregation of Revenue [Line Items]
Total revenue	5.7		40.5		9.1	8.4
Rest of world | Molecular diagnostic - Prenatal
Disaggregation of Revenue [Line Items]
Total revenue	0.2		0.6		0.3	0
Rest of world | Molecular diagnostic - Pharmacogenomics
Disaggregation of Revenue [Line Items]
Total revenue	0		0		0	0
Rest of world | Molecular diagnostic - Autoimmune
Disaggregation of Revenue [Line Items]
Total revenue	0		0		0	0
Rest of world | Molecular diagnostic - Other
Disaggregation of Revenue [Line Items]
Total revenue	0		0.5		0.1	0.4
Rest of world | Pharmaceutical and clinical services
Disaggregation of Revenue [Line Items]
Total revenue	$ 0.1		$ 0		$ 15.3	$ 23.9

Organization and Summary of S_7

Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Reconciliation of Deferred Revenue
Deferred revenue - beginning balance	$ 32.8	$ 32.7	$ 2.2	$ 2.6
Revenue recognized	(6.1)	(40.5)	(7.2)	(7.9)
Prepayments	6	14	37.8	7.5
Divestitures	0	(1)	0	0
Deferred revenue - ending balance	$ 32.7	$ 5.2	$ 32.8	$ 2.2

Organization and Summary of S_8

Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details) - shares shares in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Accounting Policies [Abstract]
Weighted-average shares outstanding used to compute basic EPS	75	74.1	78	74.8	74.3	73.5
Effect of dilutive stock options	0		0		0	2.5
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS	75	74.1	78	74.8	74.3	76
Anti-dilutive options and RSUs excluded from EPS computation	6.6		4.5		5.5	0.8

Organization and Summary of S_9

Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Cumulative Translation Adjustments
Beginning balance	$ (3.1)
Period translation adjustments	(1.8)
Ending balance	$ (4.9)

Marketable Investment Securit_3

Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Cash and cash equivalents:
Cash and cash equivalents, Amortized cost	$ 258.4	$ 117
Cash and cash equivalents, Estimated fair value	258.4	117
Total:
Total, Amortized cost	398.9	170.9
Total, Gross unrealized holding gains	0.1	0.8
Total, Gross unrealized holding gains	(0.2)	0
Total, Estimated fair value	398.8	171.7
Cash
Cash and cash equivalents:
Cash and cash equivalents, Amortized cost	195.2	47.9
Cash and cash equivalents, Estimated fair value	195.2	47.9
Cash equivalents
Cash and cash equivalents:
Cash and cash equivalents, Amortized cost	63.2	69.1
Cash and cash equivalents, Estimated fair value	63.2	69.1
Corporate bonds and notes
Available-for-sale:
Available-for-sale, Amortized cost	105.7	28.8
Available-for-sale, Gross unrealized holding gains	0.1	0.5
Available-for-sale, Gross unrealized holding losses	(0.2)	0
Available-for-sale, Estimated fair value	105.6	29.3
Municipal bonds
Available-for-sale:
Available-for-sale, Amortized cost	16.1	9.4
Available-for-sale, Gross unrealized holding gains	0	0.2
Available-for-sale, Gross unrealized holding losses	0	0
Available-for-sale, Estimated fair value	16.1	9.6
Federal agency issues
Available-for-sale:
Available-for-sale, Amortized cost	6.8	4
Available-for-sale, Gross unrealized holding gains	0	0
Available-for-sale, Gross unrealized holding losses	0	0
Available-for-sale, Estimated fair value	6.8	4
US government securities
Available-for-sale:
Available-for-sale, Amortized cost	11.9	11.7
Available-for-sale, Gross unrealized holding gains	0	0.1
Available-for-sale, Gross unrealized holding losses	0	0
Available-for-sale, Estimated fair value	$ 11.9	$ 11.8

Marketable Investment Securit_4

Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Amortized cost
Cash and cash equivalents	$ 258.4	$ 117
Available-for-sale, Due within one year	80.3
Available-for-sale, Due after one year through five years	60.2
Available-for-sale, Due after five years	0
Total, Amortized cost	398.9	170.9
Estimated fair value
Cash and cash equivalents	258.4	117
Available-for-sale, Due within one year	80.4
Available-for-sale, Due after one year through five years	60
Available-for-sale, Due after five years	0
Total, Estimated fair value	398.8	171.7
Cash
Amortized cost
Cash and cash equivalents	195.2	47.9
Estimated fair value
Cash and cash equivalents	195.2	47.9
Cash equivalents
Amortized cost
Cash and cash equivalents	63.2	69.1
Estimated fair value
Cash and cash equivalents	$ 63.2	$ 69.1

Marketable Investment Securit_5

Marketable Investment Securities - Narrative (Details) - security	Dec. 31, 2021	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Debt securities, available-for-sale, in unrealized loss position	0	0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details)	12 Months Ended
	Dec. 31, 2021
Level 3 | Measurement input, expected term
Fair Value, Balance Sheet Grouping [Line Items]
Measurement period for earn out liability	13 years 6 months

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 195	$ 112.9
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	63.2	69.1
Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	105.6	29.3
Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	16.1	9.6
Federal agency issues
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	6.8	4
US government securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	11.9	11.8
Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	(8.6)	(10.9)
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	63.2	69.1
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	63.2	69.1
Level 1 | Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 1 | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 1 | Federal agency issues
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 1 | US government securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 1 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	140.4	54.7
Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 2 | Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	105.6	29.3
Level 2 | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	16.1	9.6
Level 2 | Federal agency issues
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	6.8	4
Level 2 | US government securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	11.9	11.8
Level 2 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	(8.6)	(10.9)
Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 3 | Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 3 | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 3 | Federal agency issues
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 3 | US government securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 3 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ (8.6)	$ (10.9)

Fair Value Measurements - Chang

Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Reconciliation of change in fair value of contingent consideration
Beginning balance	$ 6.8	$ 10.9	$ 13.8	$ 14.5
Payment of contingent consideration	(0.1)	(3.3)	(3.9)	0
Change in fair value recognized in the statement of operations	3.5	1.8	(2.8)	(1.1)
Translation adjustments recognized in other comprehensive income (loss)	0.7	(0.8)	(0.3)	0.4
Ending balance	$ 10.9	$ 8.6	$ 6.8	$ 13.8

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Balances (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 150.4	$ 153.6
Less accumulated depreciation	(106.9)	(112.9)
Property, plant and equipment, net	43.5	40.7
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	38	35.7
Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 112.4	$ 117.9

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Myriad RBM, Inc. and Myriad Autoimmune business
Property, Plant and Equipment [Line Items]
Property, plant and equipment sold and deconsolidated	$ 3.1

Property, Plant and Equipment_5

Property, Plant and Equipment, Net - Depreciation Expense (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 5	$ 12.1	$ 11	$ 13.7

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 329.2
Divestitures	(88.5)
Translation adjustments	(1.5)
Carrying amount at end of period	$ 239.2

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Narrative (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019	Sep. 13, 2021
Goodwill And Intangible Assets [Line Items]
Goodwill impairment charge	$ 0	$ 0		$ 0
Impairment of long-lived assets	$ 0	$ 0	$ 17,700,000	$ 0
Weighted average remaining amortization period		10 years
Disposed of by sale | Myriad RBM, Inc. and Myriad Autoimmune business
Goodwill And Intangible Assets [Line Items]
Net decrease in intangible assets due to sale					$ 120,000,000
Accumulated amortization on intangible assets included in sale					(91,600,000)
Purchased licenses and technologies | Disposed of by sale | Myriad RBM, Inc. and Myriad Autoimmune business
Goodwill And Intangible Assets [Line Items]
Intangible assets included in sale					199,100,000
Purchased licenses and technologies | Minimum
Goodwill And Intangible Assets [Line Items]
Estimated remaining useful life	1 year
Purchased licenses and technologies | Maximum
Goodwill And Intangible Assets [Line Items]
Estimated remaining useful life	14 years
Customer relationships | Disposed of by sale | Myriad RBM, Inc. and Myriad Autoimmune business
Goodwill And Intangible Assets [Line Items]
Intangible assets included in sale					4,700,000
Trademarks | Disposed of by sale | Myriad RBM, Inc. and Myriad Autoimmune business
Goodwill And Intangible Assets [Line Items]
Intangible assets included in sale					3,000,000
In-process research and development | Disposed of by sale | Myriad RBM, Inc. and Myriad Autoimmune business
Goodwill And Intangible Assets [Line Items]
Intangible assets included in sale					$ 4,800,000
Myriad Autoimmune reporting unit
Goodwill And Intangible Assets [Line Items]
Goodwill impairment charge			80,700,000
Clinic reporting unit
Goodwill And Intangible Assets [Line Items]
Goodwill impairment charge			$ 1,300,000

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable		$ 825.9
Accumulated Amortization	$ (212.5)	(254.2)
Total, net, amortizable	404.1	571.7
Non-amortizable		4.8
Gross Carrying Amount, total	616.6	830.7
Net, total	404.1	576.5
Purchased licenses and technologies
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable	616.6	818.2
Accumulated Amortization	(212.5)	(248.2)
Total, net, amortizable	$ 404.1	570
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable		4.7
Accumulated Amortization		(4.5)
Total, net, amortizable		0.2
Trademarks
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable		3
Accumulated Amortization		(1.5)
Total, net, amortizable		1.5
In-process research and development
Intangible Assets [Line Items]
Non-amortizable		$ 4.8

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization on Intangible Assets (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 30.8	$ 50.7	$ 61	$ 59.3

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Future Amortization Expense
2022	$ 40.8
2023	40.8
2024	40.8
2025	40.8
2026	40.8
Thereafter	200.1
Total, net, amortizable	$ 404.1	$ 571.7

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 52.8	$ 48.9
Legal charges pending settlement	62	0
Accrued taxes payable	4	4.3
Refunds payable and reserves	9.8	9.3
Short-term contingent consideration	3.2	3.4
Accrued royalties	5.4	3.8
Other accrued liabilities	19.3	9.4
Total accrued liabilities	$ 156.5	$ 79.1

Long Term Debt (Details)

Long Term Debt (Details) - USD ($)	Jul. 01, 2022	Jul. 30, 2021	Jul. 31, 2018	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2022	Sep. 30, 2021	Feb. 21, 2021	Dec. 23, 2016
Debt Instrument [Line Items]
Principal repayment				$ 0	$ 226,400,000	$ 8,600,000	$ 115,000,000
Long-term debt				224,800,000	0
Revolving credit facility | Amended facility
Debt Instrument [Line Items]
Maturity date			Jul. 31, 2023
Maximum aggregate principal commitment			$ 350,000,000	$ 350,000,000	$ 250,000,000				$ 250,000,000	$ 300,000,000	$ 300,000,000
Minimum liquidity covenant										150,000,000
Minimum unrestricted cash and cash equivalents threshold per covenant										$ 150,000,000
Principal repayment		$ 106,400,000
Revolving credit facility | Amended facility | Forecast
Debt Instrument [Line Items]
Undrawn fee (percent)								0.50%
LIBOR floor (percent)								1.00%
Revolving credit facility | Amended facility | Forecast | Minimum
Debt Instrument [Line Items]
Undrawn fee (percent)	0.25%
Revolving credit facility | Amended facility | Forecast | Maximum
Debt Instrument [Line Items]
Undrawn fee (percent)	0.45%
Revolving credit facility | Amended facility | LIBOR | Forecast
Debt Instrument [Line Items]
Basis spread on rate (percent)								3.50%
Revolving credit facility | Amended facility | LIBOR | Forecast | Minimum
Debt Instrument [Line Items]
Basis spread on rate (percent)	1.50%
Revolving credit facility | Amended facility | LIBOR | Forecast | Maximum
Debt Instrument [Line Items]
Basis spread on rate (percent)	2.50%

Other Long-Term Liabilities (De

Other Long-Term Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Contingent consideration	$ 5.4	$ 7.4
Other	0.2	7.3
Total other long-term liabilities	$ 5.6	$ 14.7

Preferred and Common Stockhol_3

Preferred and Common Stockholders' Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2016
Equity [Abstract]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value (dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	150,000,000	150,000,000
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued	75,400,000	80,000,000	74,700,000	73,500,000	70,600,000
Common stock, shares outstanding	75,400,000	80,000,000	74,700,000	73,500,000	70,600,000
Stock repurchase program, authorized amount						$ 200
Stock repurchase program, remaining repurchase authorization		$ 110.7
Repurchase of Company stock	$ 0	$ 0	$ 0	$ 50

Preferred and Common Stockhol_4

Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details) - shares shares in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Common shares issued and outstanding
Beginning common stock issued	74.7	75.4	73.5	70.6
Beginning common stock outstanding	74.7	75.4	73.5	70.6
Common stock issued upon exercise of options and employee stock plans	0.7	4.6	1.2	4.5
Repurchase and retirement of common stock	0	0	0	(1.6)
Ending common stock issued	75.4	80	74.7	73.5
Ending common stock outstanding	75.4	80	74.7	73.5

Preferred and Common Stockhol_5

Preferred and Common Stockholders' Equity - Stock Repurchases (Details) - USD ($) shares in Millions, $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Equity [Abstract]
Shares purchased and retired	0	0	0	1.6
Common stock and additional paid-in-capital reductions	$ 0	$ 0	$ 0	$ 16.9
Charges to retained earnings	$ 0	$ 0	$ 0	$ 33.1
Common stock, shares issued	75.4	80	74.7	73.5	70.6

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Sep. 23, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019	Dec. 05, 2012
Share-based Compensation [Line Items]
Options granted (shares)				0	0	0
Unrecognized stock-based compensation expense		$ 61.7		$ 61.7
Weighted-average period for recognition (years)				2 years 3 months 18 days
2017 Plan
Share-based Compensation [Line Items]
Number of shares authorized		4,600,000		4,600,000
Shares available for grant		3,600,000		3,600,000
2012 Purchase Plan
Share-based Compensation [Line Items]
Number of shares authorized							2,000,000
Additional shares available for future grant	2,000,000
Maximum number of shares per participant per offering period	5,000
Shares issued under the Plan		2,000,000
President and Chief Executive Officer
Share-based Compensation [Line Items]
Options granted (shares)			700,000
Weighted average grant date fair value of options granted (dollars per share)			$ 13.38
Options and RSUs | Non-employee director
Share-based Compensation [Line Items]
Service period for award vesting (in years)				1 year
Stock options
Share-based Compensation [Line Items]
Service period for award vesting (in years)				4 years
Award expiration period (in years)				10 years
Stock options | President and Chief Executive Officer
Share-based Compensation [Line Items]
Award expiration period (in years)				7 years
RSUs
Share-based Compensation [Line Items]
Service period for award vesting (in years)				4 years
Weighted average grant date fair value (dollars per share)			$ 13.69	$ 29.83	$ 27.96	$ 46.62
Fair value of restricted stock units that vested			$ 29.1	$ 22.6	$ 32.4	$ 27.6
RSUs | Certain executive officers and other senior positions | Achievement levels based on EPS targets
Share-based Compensation [Line Items]
Vesting weight (percent)				50.00%
RSUs | Certain executive officers and other senior positions | Performance based on Nasdaq Healthcare Provider Index
Share-based Compensation [Line Items]
Vesting weight (percent)				50.00%

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Options, Number of shares
Options outstanding, beginning (shares)	5,200,000
Options granted (shares)	0	0	0
Options exercised (shares)	(3,700,000)
Options canceled or expired (shares)	(100,000)
Options outstanding, ending (shares)	1,400,000
Options exercisable (shares)	1,000,000
Options vested and expected to vest (shares)	1,400,000
Options, Weighted average exercise price
Options outstanding, beginning (dollars per share)	$ 23.24
Options granted (dollars per share)	0
Options exercised (dollars per share)	24.26
Options canceled or expired (dollars per share)	25.18
Options outstanding, ending (dollars per share)	20.36
Options exercisable (dollars per share)	23.07
Options vested and expected to vest (dollars per share)	$ 20.36
Options, Weighted average remaining contractual life (in years)
Options outstanding, Weighted average remaining contractual life (years)	3 years 29 days
Options exercisable, Weighted average remaining contractual life (years)	2 years 1 month 2 days
Options vested and expected to vest, Weighted average remaining contractual life (years)	3 years 29 days

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock Options Outstanding (Details) shares in Millions	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in shares) | shares	1.4
Weighted average remaining contractual life (years)	3 years 29 days
Weighted average exercise price (in dollars per share)	$ 20.38
$ 13.38
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, minimum (in dollars per share)	$ 13.38
Number outstanding (in shares) | shares	0.7
Weighted average remaining contractual life (years)	5 years 7 months 13 days
Weighted average exercise price (in dollars per share)	$ 13.38
$ 23.98
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, minimum (in dollars per share)	$ 23.98
Number outstanding (in shares) | shares	0.1
Weighted average remaining contractual life (years)	2 months 4 days
Weighted average exercise price (in dollars per share)	$ 23.98
$ 27.07 - 36.55
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, minimum (in dollars per share)	27.07
Range of exercise prices, maximum (in dollars per share)	$ 36.55
Number outstanding (in shares) | shares	0.6
Weighted average remaining contractual life (years)	8 months 26 days
Weighted average exercise price (in dollars per share)	$ 27.25

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Activity (Details) - RSUs - $ / shares shares in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
RSUs, Number of shares
RSUs unvested and outstanding, beginning (shares)		3.2
RSUs granted (shares)		1.8
RSUs vested (shares)		(1.1)
RSUs canceled (shares)		(0.8)
RSUs unvested and outstanding, ending (shares)	3.2	3.1
RSUs, Weighted average grant date fair value
RSUs unvested and outstanding, beginning (dollars per share)		$ 20.56
RSUs granted (dollars per share)	$ 13.69	29.83	$ 27.96	$ 46.62
RSUs vested (dollars per share)		21.32
RSUs canceled (dollars per share)		24.48
RSUs unvested and outstanding, ending (dollars per share)	$ 20.56	$ 24.96

Stock-Based Compensation - St_3

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	$ 14.9	$ 36.3	$ 25.2	$ 33.5
Cost of molecular diagnostic testing
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	0.6	1.5	1.2	0.8
Cost of pharmaceutical and clinical services
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	0.1	0.1	0.3	0.2
Research and development expense
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	2.4	4.2	5	5.4
Selling, general, and administrative expense
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	$ 11.8	$ 30.5	$ 18.7	$ 27.1

Stock-Based Compensation - Aggr

Stock-Based Compensation - Aggregate Intrinsic Value (Details) $ in Millions	Dec. 31, 2021USD ($)
Share-based Compensation [Line Items]
Aggregate intrinsic value of options outstanding	$ 10.2
Aggregate intrinsic value of options fully vested	4.6
RSUs
Share-based Compensation [Line Items]
Aggregate intrinsic value of RSUs outstanding	$ 86.3

Stock-Based Compensation - Intr

Stock-Based Compensation - Intrinsic Value of Options Exercised (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Total intrinsic value of options exercised	$ 0.5	$ 29.2	$ 8.8	$ 0.4

Stock-Based Compensation - Shar

Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details) - 2012 Purchase Plan - USD ($) shares in Millions, $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation [Line Items]
Shares purchased under the plans	0.1	0.2	0.3	0.2
Plan compensation expense	$ 0.6	$ 1.5	$ 1.7	$ 1

Stock-Based Compensation - Valu

Stock-Based Compensation - Valuation Assumptions for ESPP (Details) - 2012 Purchase Plan	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Valuation Assumptions
Risk-free interest rate	0.20%	0.10%	1.80%	2.10%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Expected life (in years)	6 months	6 months	6 months	6 months
Expected volatility	94.00%	60.00%	99.00%	55.00%

Income Taxes - Income Tax Benef

Income Taxes - Income Tax Benefit (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Current:
Federal	$ (75.8)		$ (1.9)		$ 26.6	$ (24.2)
State	(0.6)		3.6		4.9	(0.1)
Foreign	0.2		0.1		0.5	0.2
Total current	(76.2)		1.8		32	(24.1)
Deferred:
Federal	39.1		(33.7)		(51.5)	17.8
State	(3.4)		5.1		(4.1)	1.7
Foreign	(0.5)		0.1		(3.6)	0.4
Change in valuation allowance	0		(3.2)		3.5	(0.2)
Total deferred	35.2		(31.7)		(55.7)	19.7
Total income tax benefit	$ (41)	$ (4.8)	$ (29.9)	$ (59.9)	$ (23.7)	$ (4.4)

Income Taxes - Income (Loss) Be

Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Income (loss) before income taxes:
United States	$ (101.8)		$ (53.8)		$ (240.9)	$ (0.6)
Foreign	7.7		(3.3)		17.6	0.6
Income (loss) before income tax	$ (94.1)	$ (33.7)	$ (57.1)	$ (283.6)	$ (223.3)	$ 0

Income Taxes - Statutory Federa

Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Effective Income Tax Rate Reconciliation, Amount
Federal income tax expense at the statutory rate	$ (19.8)		$ (12)		$ (46.9)	$ 0
State income taxes, net of federal benefit	(1.2)		(1.8)		4	2
Research and development credits	(1.3)		2.5		(2.8)	(3.7)
Uncertain tax positions	0.6		(3)		1.5	(4.2)
Incentive stock option and employee stock purchase plan expense	2.5		0.7		(0.2)	(3.1)
Foreign rate differential	(2.1)		0.5		0.7	0.8
Change in valuation allowance	(0.3)		(3.2)		3.5	(0.2)
CARES Act	(20.7)		2.7
Non-deductible meals and entertainment	0.5		0.1		1.8	1.3
Non-deductible officer compensation	0.1		3.3		1.6	0.6
Asset impairment	0		0		12.6	0
Non-deductible legal settlement	0		2.5		0	1.9
Acquisitions, Dispositions, and Contingent Consideration	0.7		(23)		(0.3)	0.8
Method changes or tax elections	0		0		0	(0.9)
Other, net	0		0.8		0.8	0.3
Total income tax benefit	$ (41)	$ (4.8)	$ (29.9)	$ (59.9)	$ (23.7)	$ (4.4)
Effective Income Tax Rate Reconciliation, Percent
Federal income tax expense at the statutory rate	21.00%		21.00%		21.00%	21.00%
State income taxes, net of federal benefit	1.30%		3.20%		(1.80%)	6422.10%
Research and development credits	1.40%		(4.40%)		1.30%	(11880.90%)
Uncertain tax positions	(0.70%)		5.30%		(0.70%)	(13486.40%)
Incentive stock option and employee stock purchase plan expense	(2.70%)		(1.20%)		0.10%	(9954.30%)
Foreign rate differential	2.20%		(0.90%)		(0.30%)	2568.80%
Change in valuation allowance	0.30%		5.60%		(1.70%)	(642.20%)
CARES Act	22.00%		(4.70%)
Non-deductible meals and entertainment	(0.50%)		(0.20%)		(0.80%)	4174.40%
Non-deductible officer compensation	(0.10%)		(5.80%)		(0.70%)	1926.60%
Asset impairment	0.00%		0.00%		(5.60%)	0.00%
Non-deductible legal settlement	0.00%		(4.50%)		0.00%	6101.00%
Acquisitions, Dispositions, and Contingent Consideration	(0.70%)		40.30%		0.10%	2568.80%
Method changes or tax elections	0.00%		0.00%		0.00%	(2890.00%)
Other, net	0.00%		(1.40%)		(0.30%)	963.40%
Total income tax benefit	43.50%		52.30%		10.60%	(14107.70%)

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carryforwards	$ 67.2	$ 72.2
Deferred revenue	1.2	7.2
Stock compensation expense	4.5	11.5
Research and development credits	17.3	24.9
Lease right-of-use asset	22.4	15.2
Accrued expenses and liabilities	14.2	7.6
Other, net	4.5	6.4
Total gross deferred tax assets	131.3	145
Less valuation allowance	(38.5)	(42)
Total deferred tax assets	92.8	103
Deferred tax liabilities:
Intangible assets	104.9	144
Lease liability	20.2	14.6
Property, plant and equipment	3.5	15.7
Total deferred tax liabilities	128.6	174.3
Net deferred tax liability	$ (35.8)	$ (71.3)

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)divestiture	Dec. 31, 2020USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)
Income Tax Contingency [Line Items]
Tax expense (benefit) related to operating loss carryback, CARES Act	$ (2.7)	$ (20.7)
Capital loss for the tax basis on stock	187
Overall capital gain on divestitures	$ 282.3
Number of divestitures | divestiture	3
Overall net tax benefit of divestitures	$ 23.4
Decrease in valuation allowance	3.5
Unrecognized tax benefits	$ 32.1	$ 37.6	$ 23.5	$ 21.7	$ 24.9
State and local jurisdictions | California | Earliest tax year
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2017
State and local jurisdictions | California | Latest tax years
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2018
State and local jurisdictions | New Jersey | Earliest tax year
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2013
State and local jurisdictions | New Jersey | Latest tax years
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2017
Foreign | Switzerland | Earliest tax year
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2015
Foreign | Switzerland | Latest tax years
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination	2016

Income Taxes - Net Operating Lo

Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Federal | Federal
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 31.2
Net operating loss subject to sections 382,383	Yes
Federal | Federal | Minimum
Operating Loss Carryforwards [Line Items]
Net operating loss, expiration in year	2036
Federal | Federal | Maximum
Operating Loss Carryforwards [Line Items]
Net operating loss, expiration in year	2037
Federal | Federal | Capital loss
Operating Loss Carryforwards [Line Items]
Tax credit	$ 13.5
Tax credit subject to sections 382,383	No
Federal | Federal | Capital loss | Minimum
Operating Loss Carryforwards [Line Items]
Tax credit, expiration in year	2026
Federal | Federal | Capital loss | Maximum
Operating Loss Carryforwards [Line Items]
Tax credit, expiration in year	2026
Federal | Federal | Research credit
Operating Loss Carryforwards [Line Items]
Tax credit	$ 6.4
Tax credit subject to sections 382,383	Yes
Federal | Federal | Research credit | Minimum
Operating Loss Carryforwards [Line Items]
Tax credit, expiration in year	2027
Federal | Federal | Research credit | Maximum
Operating Loss Carryforwards [Line Items]
Tax credit, expiration in year	2042
State | Utah
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 2.4
Net operating loss subject to sections 382,383	No
State | Utah | Minimum
Operating Loss Carryforwards [Line Items]
Net operating loss, expiration in year	2022
State | Utah | Research credit
Operating Loss Carryforwards [Line Items]
Tax credit	$ 6.9
Tax credit subject to sections 382,383	No
State | Utah | Research credit | Minimum
Operating Loss Carryforwards [Line Items]
Tax credit, expiration in year	2022
State | Utah | Research credit | Maximum
Operating Loss Carryforwards [Line Items]
Tax credit, expiration in year	2036
State | California
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 3.9
Net operating loss subject to sections 382,383	Yes
State | California | Minimum
Operating Loss Carryforwards [Line Items]
Net operating loss, expiration in year	2027
State | California | Maximum
Operating Loss Carryforwards [Line Items]
Net operating loss, expiration in year	2042
State | California | Research credit
Operating Loss Carryforwards [Line Items]
Tax credit	$ 4
Tax credit subject to sections 382,383	No
State | Other
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 7.4
Net operating loss subject to sections 382,383	Yes
State | Other | Minimum
Operating Loss Carryforwards [Line Items]
Net operating loss, expiration in year	2027
State | Other | Maximum
Operating Loss Carryforwards [Line Items]
Net operating loss, expiration in year	2041
Foreign
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 8.8
Net operating loss subject to sections 382,383	No

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Unrecognized Tax Benefits
Unrecognized tax benefits at the beginning of period	$ 23.5	$ 37.6	$ 21.7	$ 24.9
Gross increases - current year tax positions	13.9	1.4	1.6	2.2
Gross increases - prior year tax positions	1	1.1	0.7	0.5
Gross increases - acquisitions	0	0	0	2.3
Gross decreases - prior year tax positions	(0.1)	(2.8)	0	(0.1)
Gross decreases - settlements	0	(5.1)	0	(2.7)
Gross decreases - statute lapse	(0.7)	(0.1)	(0.5)	(5.4)
Unrecognized tax benefits at end of year	37.6	32.1	23.5	21.7
Interest and penalties in year-end balance	$ 2.2	$ 3.3	$ 1.4	$ 0.8

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	Jan. 24, 2022	Dec. 31, 2021	Dec. 31, 2020
Loss Contingencies [Line Items]
Legal charges pending settlement		$ 62	$ 0
CBI
Loss Contingencies [Line Items]
Legal charges pending settlement		48
Abelli and Pricolo
Loss Contingencies [Line Items]
Legal charges pending settlement		$ 14
Abelli and Pricolo | Subsequent event
Loss Contingencies [Line Items]
Settlement agreement	$ 14

Leases - Narrative (Details)

Leases - Narrative (Details) ft² in Thousands, $ in Millions	1 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2021ft²	Dec. 31, 2020USD ($)	Dec. 31, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)
Lessee, Lease, Description [Line Items]
Lease cost		$ 9.9	$ 20.7	$ 18.4
Variable lease expense		1.8	$ 3.2	2.6
Short-term lease expense		$ 0.1		$ 0.2
Rent expense (prior to adoption of ASU 2016-02)					$ 19.7
Operating lease weighted average remaining lease term	8 years 8 months 12 days		8 years 8 months 12 days
Operating lease weighted average discount rate	5.10%		5.10%
South San Francisco, California
Lessee, Lease, Description [Line Items]
Operating lease area (sq ft) | ft²	63
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	1 year		1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	14 years		14 years

Leases - Maturities of Operatin

Leases - Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Maturities of operating lease liabilities
2022	$ 17.4
2023	19.8
2024	22.4
2025	16.6
2026	14.7
Thereafter	88.1
Total future lease payments	179
Less: amounts representing interest	(27.9)
Present value of future lease payments	151.1
Less: leases not yet commenced	(58.8)
Less: current maturities of operating lease liabilities	(13)	$ (13.6)
Noncurrent operating lease liabilities	$ 79.3	$ 50.6

Employee Deferred Savings Pla_2

Employee Deferred Savings Plan - Narrative (Details)	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Company matching contribution as percentage of employee contribution	50.00%
Company matching contribution, maximum as percentage of employee compensation	4.00%

Employee Deferred Savings Pla_3

Employee Deferred Savings Plan - Contributions to Plan (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Retirement Benefits [Abstract]
Deferred savings plan contributions	$ 4	$ 8.4	$ 7.1	$ 8.3

Segment and Related Informati_3

Segment and Related Information - Narrative (Details)	12 Months Ended
	Dec. 31, 2021segment
Segment Reporting [Abstract]
Number of reportable segments	1

Segment and Related Informati_4

Segment and Related Information - Assets by Geographical Region (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	$ 43.5	$ 40.7
Cash, cash equivalents, and marketable investment securities	398.8	171.7
Total assets	1,320.7	1,418.8
Reportable geographical components
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	43.6	40.7
Total	921.9	1,247.1
Reportable geographical components | United States
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	41.7	38.4
Total	870.8	1,190.3
Reportable geographical components | Rest of world
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	1.9	2.3
Total	$ 51.1	$ 56.8

Divestitures - Narrative (Detai

Divestitures - Narrative (Details) - USD ($) $ in Millions	Sep. 13, 2021	Jul. 01, 2021	May 28, 2021	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Disposal of Subsidiary [Line Items]
Loss on non-cancelable purchase commitment					$ 5.2
Loss on inventory				$ 0	6.5	$ 0	$ 0
Disposed of by sale | Myriad myPath LLC laboratory
Disposal of Subsidiary [Line Items]
Proceeds from sale of assets			$ 32.5
Net gain on sale of assets adjusted for transaction fees			31.2
Gain (loss) on sale of subsidiary					31.2
Transaction costs			$ 1.3
Disposed of by sale | Myriad RBM, Inc.
Disposal of Subsidiary [Line Items]
Proceeds from sale of business		$ 197
Gain (loss) on sale of subsidiary		121			121
Transaction costs		$ 4.8
Disposed of by sale | Select operating assets and intellectual property of Myriad Autoimmune business unit
Disposal of Subsidiary [Line Items]
Proceeds from sale of business	$ 150
Gain (loss) on sale of subsidiary	(0.6)				$ (0.6)
Transaction costs	$ 4.4

Divestitures - Other Income (De

Divestitures - Other Income (Details) - USD ($) $ in Millions	Sep. 13, 2021	Jul. 01, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Disposal of Subsidiary [Line Items]
Total Other Income			$ (1.2)	$ (0.3)	$ 139.3	$ 15.3	$ 16.2	$ 1.2
Disposed of by sale
Disposal of Subsidiary [Line Items]
Loss on inventory					(11.7)
Other					(0.6)
Myriad RBM, Inc. | Disposed of by sale
Disposal of Subsidiary [Line Items]
Gain (loss) on sale of subsidiary		$ 121			121
Myriad myPath LLC laboratory | Disposed of by sale
Disposal of Subsidiary [Line Items]
Gain (loss) on sale of subsidiary					31.2
Myriad Autoimmune assets | Disposed of by sale
Disposal of Subsidiary [Line Items]
Gain (loss) on sale of subsidiary	$ (0.6)				$ (0.6)

Business Acquisitions - Narrati

Business Acquisitions - Narrative (Details) - Counsyl Inc - USD ($) $ in Millions	Jul. 31, 2018	Jun. 30, 2019
Business Acquisition [Line Items]
Business acquisition consideration	$ 405.9
Acquisition costs	$ 6.8
Revenue contributed by acquired entity		$ 104.9
Operating expenses related to acquired entity		$ 67.6

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent event - Salt Lake City ft² in Thousands, $ in Millions	2 Months Ended
	Feb. 24, 2022USD ($)ft²
Subsequent Event [Line Items]
Operating lease area (sq ft) | ft²	230
Lease term (in years)	15 years
Total future lease payments | $	$ 77.8

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Cash paid for income taxes	$ 1.8	$ 4.6	$ 1	$ 6.5
Cash paid for interest	5.2	4.4	9.5	11.6
Cash received for income tax receivables	0	90	0	0
Establishment of operating lease right-of-use assets and lease liabilities
Operating lease right-of-use assets	0	41.8	74.5	0
Operating lease liabilities	0	(48.1)	(78.8)	0
Accrued liabilities and other long-term liabilities	$ 0	$ 0	$ 4.3	$ 0

Transition Period Comparative_3

Transition Period Comparative Data (Unaudited) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Transition Period Financial Information [Line Items]
Total revenue	$ 299.8	$ 381.4	$ 690.6	$ 557.1	$ 638.6	$ 851.1
Costs and expenses:
Research and development expense	35.8	40.1	81.9	73.3	77.2	85.9
Selling, general, and administrative expense	260.4	270.4	537.8	496.9	507.3	556.6
Goodwill and long-lived asset impairment charges	0	1.3	1.8	98.4	99.7	0
Total costs and expenses	387.6	411.1	881.1	846.8	870.3	843.5
Operating income (loss)	(87.8)	(29.7)	(190.5)	(289.7)	(231.7)	7.6
Other income (expense):
Interest income	0.7	1.7	0.7	2	3	3.2
Interest expense	(5.8)	(5.4)	(6.6)	(11.2)	(10.8)	(12)
Other	(1.2)	(0.3)	139.3	15.3	16.2	1.2
Total other income (expense)	(6.3)	(4)	133.4	6.1	8.4	(7.6)
Income (loss) before income tax	(94.1)	(33.7)	(57.1)	(283.6)	(223.3)	0
Income tax benefit	(41)	(4.8)	(29.9)	(59.9)	(23.7)	(4.4)
Net income (loss)	(53.1)	(28.9)	(27.2)	(223.7)	(199.6)	4.4
Net loss attributable to non-controlling interest	0	0	0	(0.1)	(0.1)	(0.2)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (53.1)	$ (28.9)	$ (27.2)	$ (223.6)	$ (199.5)	$ 4.6
Earnings (loss) per share:
Basic (in dollars per share)	$ (0.71)	$ (0.39)	$ (0.35)	$ (2.99)	$ (2.69)	$ 0.06
Diluted (in dollars per share)	$ (0.71)	$ (0.39)	$ (0.35)	$ (2.99)	$ (2.69)	$ 0.06
Weighted average shares outstanding:
Basic (weighted average shares)	75	74.1	78	74.8	74.3	73.5
Diluted (weighted average shares)	75	74.1	78	74.8	74.3	76
Molecular diagnostic revenues
Transition Period Financial Information [Line Items]
Total revenue	$ 279.6	$ 353.1	$ 666.4	$ 513.5	$ 586.9	$ 789.4
Costs and expenses:
Costs and expenses	82.6	82.2	185.7	157.9	157.5	168.2
Pharmaceutical and clinical services
Transition Period Financial Information [Line Items]
Total revenue	20.2	28.3	24.2	43.6	51.7	61.7
Costs and expenses:
Costs and expenses	$ 8.8	$ 17.1	$ 11.9	$ 20.3	$ 28.6	$ 32.8